fenofibrate has been researched along with Hyperlipemia in 308 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu(++)-mediated oxidation in patients with metabolic syndrome." | 9.17 | Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. ( Farkas-Epperson, M; Le, NA; Sweeney, ME; Virgil Brown, W; Wilson, PW, 2013) |
| "To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 9.14 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Burgess, DC; Davis, TM; Hunt, D; Keech, AC; Kesäniemi, YA; Laakso, M; Lehto, S; Li, L; Mann, S; Sy, RW; Williamson, E; Zannino, D; Zhang, J, 2010) |
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 9.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 9.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "The aim of this study was to compare the efficacy and safety profile of fluvastatin + fenofibrate combination therapy and those of fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus (DM), and coronary heart disease (CHD) (ie, high risk for cardiovascular disease [CVD])." | 9.11 | Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. ( Bertone, G; Ciccarelli, L; Cicero, AE; Derosa, G; Piccinni, MN; Roggeri, DE, 2004) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "Our objective was to determine whether fenofibrate modifies the metabolism of nonesterified (free) fatty acids as a component of its triglyceride-lowering action in male patients with the metabolic syndrome." | 9.10 | Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. ( Cater, NB; Grundy, SM; Hadizadeh, DR; Meguro, S; Vega, GL, 2003) |
| "We investigated the effects of fenofibrate on insulin resistance and tissue inflammation in a high-fat diet (HFD)-fed ovariectomized (OVX) C57BL/6J mice, a mouse model of obese postmenopausal women." | 8.31 | Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. ( Jeon, S; Lee, J; Lee, M; Yoon, M, 2023) |
| "To study the effects of osthole on hyperlipidemic fatty liver and investigate the possible mechanisms." | 7.74 | Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. ( Gu, ZL; Xie, ML; Zhang, Y; Zhu, LJ, 2007) |
| "To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease." | 7.71 | Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002) |
| "When fenofibrate was added to simvastatin therapy, HDL cholesterol increased significantly by 23%." | 6.71 | Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. ( Cater, NB; Filipchuk, N; Garcia-Garcia, AB; Grundy, SM; Ma, PT; Meguro, S; Vega, GL, 2003) |
| " The safety of the treatment was assessed by recording adverse events and measuring clinical laboratory parameters." | 6.71 | [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Jakóbisiak-Ostasz, B; Kłosiewicz-Latoszek, L; Respondek, W; Stolarska, I, 2003) |
| "Hypothyroidism is one of the common causes of the secondary hypercholesterolemia." | 6.43 | [Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature]. ( Brzosko, M; Lukjanowicz, M; Trzcińska-Butkiewicz, B, 2006) |
| "Saroglitazar, being a dual PPAR-α/γ agonist, has shown beneficial effect in diabetic dyslipidemia and hypertriglyceridemia." | 5.51 | Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. ( Cruz-López, P; González, JG; Parmar, D; Rodriguez-Gutierrez, R; Shaikh, F, 2022) |
| "Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu(++)-mediated oxidation in patients with metabolic syndrome." | 5.17 | Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome. ( Farkas-Epperson, M; Le, NA; Sweeney, ME; Virgil Brown, W; Wilson, PW, 2013) |
| "To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 5.14 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Burgess, DC; Davis, TM; Hunt, D; Keech, AC; Kesäniemi, YA; Laakso, M; Lehto, S; Li, L; Mann, S; Sy, RW; Williamson, E; Zannino, D; Zhang, J, 2010) |
| "Micronised fenofibrate treatment could significantly improve lipid and uric acid metabolism in patients with hypertriglyceridemia and hyperuricemia, and is generally safe and well tolerated." | 5.14 | [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia]. ( Chen, H; Li, LJ; Luo, Y; Ren, JY; Wang, L, 2009) |
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 5.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 5.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "We administered simvastatin, 20 mg daily, to 27 patients with hypercholesterolemia and coronary artery disease, or fenofibrate, 200 mg daily, to 27 patients with pure hypertriglyceridemia during 8 weeks." | 5.11 | Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. ( Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Jeong, EM; Jin, DK; Kim, HS; Koh, KK; Shin, EK, 2004) |
| "The aim of this study was to compare the efficacy and safety profile of fluvastatin + fenofibrate combination therapy and those of fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus (DM), and coronary heart disease (CHD) (ie, high risk for cardiovascular disease [CVD])." | 5.11 | Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. ( Bertone, G; Ciccarelli, L; Cicero, AE; Derosa, G; Piccinni, MN; Roggeri, DE, 2004) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "Fenofibrate is a potent hypolipemic agent, widely used in patients with renal insufficiency in whom dyslipidemia is frequent." | 5.10 | Fenofibrate increases creatininemia by increasing metabolic production of creatinine. ( Achard, JM; El Esper, N; Fournier, A; Hottelart, C; Rose, F, 2002) |
| "Our objective was to determine whether fenofibrate modifies the metabolism of nonesterified (free) fatty acids as a component of its triglyceride-lowering action in male patients with the metabolic syndrome." | 5.10 | Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. ( Cater, NB; Grundy, SM; Hadizadeh, DR; Meguro, S; Vega, GL, 2003) |
| "The long-term efficacy and safety of fluvastatin monotherapy was compared with that of the combination of fluvastatin and fenofibrate in 104 patients with coronary heart disease and combined hyperlipidemia in an open, randomised, parallel group, clinical study of 78 weeks duration." | 5.09 | [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate]. ( Balazovjech, I; Hulínský, V; Lánská, V; Widimský, J, 1999) |
| "To investigate the lipoprotein effect of fenofibrate in hypercholesterolemia or combined hyperlipidemia (types II A and II B hyperlipidemias, respectively), 240 patients were recruited and 227 randomized to a double-blind randomized trial lasting 24 weeks and 192 patients continued to participate in an open-label phase for another 24 weeks." | 5.06 | Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. ( Brown, WV; Dujovne, CA; Farquhar, JW; Feldman, EB; Goldberg, AC; Grundy, SM; Knopp, RH; Lasser, NL; Mellies, MJ; Palmer, RH, 1987) |
| " Recently, it has been shown that some of the most prescribed fibrates cause hyperhomocysteinemia, which itself has been recognised as a cardiovascular risk factor." | 4.82 | The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. ( Dierkes, J; Luley, C; Westphal, S, 2004) |
| "To review the efficacy and safety of fenofibrate in the management of hyperlipidemias." | 4.80 | Micronized fenofibrate: a new fibric acid hypolipidemic agent. ( Guay, DR, 1999) |
| "We investigated the effects of fenofibrate on insulin resistance and tissue inflammation in a high-fat diet (HFD)-fed ovariectomized (OVX) C57BL/6J mice, a mouse model of obese postmenopausal women." | 4.31 | Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice. ( Jeon, S; Lee, J; Lee, M; Yoon, M, 2023) |
| " A rat model of renal transplantation was treated with the lipid-lowering drug, fenofibrate, and kidney fibrosis levels were determined by histochemical staining." | 4.31 | Targeted changes in blood lipids improves fibrosis in renal allografts. ( Li, G; Liu, B; Meng, Q; Wang, Y; Xu, ZX; Yang, H; Zhang, D; Zhang, YH; Zhou, H, 2023) |
| "These results demonstrate that: (a) F(1)B hamster is more sensitive to developing diet-induced hyperlipidemia and atherosclerosis; and (b) the greater antiatherosclerotic efficacy of fenofibrate occurred primarily via reductions in proatherogenic lipoproteins." | 3.77 | Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. ( Srivastava, RA, 2011) |
| " In this study, we aimed to: a) evaluate hamster as a model for insulin resistance, hyperlipidemia and atherosclerosis; and b) investigate the effect of a PPAR-α activator, fenofibrate, in this model." | 3.76 | Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. ( He, S; Srivastava, RA, 2010) |
| "Recent trials have investigated the usefulness of fenofibrate, alone and in combination with other lipid-lowering therapies, in the treatment of hyperlipidemia." | 3.76 | Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs. ( Brown, WV, 1989) |
| "Fenofibrate is a fibric acid derivative with enhanced potency and specificity of action on lipids." | 3.76 | Safety of fenofibrate--US and worldwide experience. ( Roberts, WC, 1989) |
| "To study the effects of osthole on hyperlipidemic fatty liver and investigate the possible mechanisms." | 3.74 | Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. ( Gu, ZL; Xie, ML; Zhang, Y; Zhu, LJ, 2007) |
| "NO deficiency and activation of inflammation are involved in vascular impairment in rats with high-fat diet-induced hyperlipidemia, and fenofibrate can effectively prevent atherosclerosis by restoring NO concentration and down-regulating VCAM-1 expression in these rats." | 3.74 | [Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats]. ( Guo, HS; He, ZC; Lin, JC; Ou, BR; Sun, M; Wu, J, 2007) |
| "An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis." | 3.72 | Risk of adverse events with fibrates. ( Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004) |
| "To compare the lipid-lowering effects of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease." | 3.71 | Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002) |
| "To report a case of acute necrotizing pancreatitis associated with simvastatin and fenofibrate use." | 3.71 | Pancreatitis associated with simvastatin plus fenofibrate. ( Garber, BG; McDonald, KB; Perreault, MM, 2002) |
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| "The dementia of a patient with hyperlipidemia improved dramatically on treatment with diet and fenofibrate." | 3.67 | Hyperlipidemic dementia. ( Agar, N; Bousser, MG; Lacombe, C; Mas, JL, 1985) |
| "Fenofibrate use was associated with some changes in laboratory measurements, but there was no differential adverse effect between the combination therapy and fenofibrate monotherapy." | 2.84 | Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study. ( Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S, 2017) |
| " The absence of a significant pharmacokinetic interaction between fenofibrate and atorvastatin is consistent with recent results showing no difference in safety profile between atorvastatin as monotherapy or in combination with fenofibric acid." | 2.76 | Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. ( Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR, 2011) |
| "Patients with type 2 diabetes mellitus and mixed hyperlipidemia have an increased cardiovascular risk and may not achieve recommended LDL-C and non-HDL-C goals on statin monotherapy." | 2.76 | Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. ( Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A, 2011) |
| " Combination therapy was generally well tolerated with incidences of clinical and laboratory adverse experiences similar between the 2 groups." | 2.75 | Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. ( Bryniarski, L; Ducobu, J; Farnier, M, 2010) |
| "Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid mechanisms." | 2.74 | Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. ( Baker, JR; Best, JD; Colman, PG; D'Emden, MC; Keech, AC; Laakso, M; Li, LP; Rajamani, K; Voysey, M, 2009) |
| "Mixed hyperlipidemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and TG-rich lipoprotein levels." | 2.73 | Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. ( Davies, MJ; Farnier, M; Gil-Extremera, B; Hamlin, C; Kush, D; Macdonell, G; Mendez, GF; Mitchel, YB; Perevozskaya, I; Roth, E, 2007) |
| "In the postprandial lipemia after a fat load, the 56G carriers showed a significant decrease in the area under curve for TG and increase for HDL-C than the noncarriers." | 2.73 | Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. ( Adiconis, X; Arnett, DK; Corella, D; Hixson, JE; Lai, CQ; Ordovas, JM; Parnell, LD; Peacock, JM; Province, MA; Straka, RJ; Tsai, MY, 2007) |
| "Mixed hyperlipidemia is a major cause of coronary artery disease." | 2.73 | Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia. ( Badyal, DK; Calton, R; Chatley, P; Khosla, PP, 2007) |
| "Atorvastatin was significantly more effective in reducing total cholesterol, LDL cholesterol, apolipoprotein B, and non-high-density lipoprotein (HDL) cholesterol." | 2.73 | Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. ( Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G, 2007) |
| "Eighteen patients with hyperlipidemia and type 2 diabetes mellitus." | 2.72 | Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus. ( Asano, A; Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Murase, Y; Nohara, A; Shimizu, M, 2006) |
| "-11." | 2.71 | Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia. ( Ducobu, J; Salomon, H; VanHaelst, L, 2003) |
| "When fenofibrate was added to simvastatin therapy, HDL cholesterol increased significantly by 23%." | 2.71 | Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. ( Cater, NB; Filipchuk, N; Garcia-Garcia, AB; Grundy, SM; Ma, PT; Meguro, S; Vega, GL, 2003) |
| "Patients with combined hyperlipidemia (n = 37) were randomized to receive 9 weeks of treatment with micronized fenofibrate 200 mg/day (F group) or fenofibrate 200 mg/day plus folic acid 10 mg/every other day (F+F group)." | 2.71 | Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. ( Ceska, R; Grauova, B; Haas, T; Hradec, J; Kozich, V; Krijt, J; Malik, J; Melenovsky, V; Stulc, T; Wichterle, D, 2003) |
| "Patients with IHD and combined hyperlipidemia with (n=56)) or without type 2 diabetes (n=30)." | 2.71 | [Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes]. ( Kozlov, SG; Liakishev, AA; Naumov, VG; Sarano, NE; Tvorogova, MG, 2003) |
| " The safety of the treatment was assessed by recording adverse events and measuring clinical laboratory parameters." | 2.71 | [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Jakóbisiak-Ostasz, B; Kłosiewicz-Latoszek, L; Respondek, W; Stolarska, I, 2003) |
| "Treatment with fenofibrate did not alter plasma ADMA level, in contrast to serum triglycerides which were significantly lowered and plasma total homocysteine which was significantly increased." | 2.71 | Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. ( Bode-Böger, SM; Dierkes, J; Luley, C; Martens-Lobenhoffer, J; Westphal, S, 2004) |
| "Treatment with atorvastatin and fenofibrate reduced serum cholesterol by 30 % and 21 % (p = 0." | 2.71 | Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. ( Baumstark, MW; Friedrich, I; Hauck, P; Hoffmann, MM; März, W; Nickell, HH; Schmitz, H; Weltzien, P; Wieland, H; Winkler, K, 2004) |
| "Twenty Type 2 diabetic patients with dyslipidemia were treated 3 months with simvastatin (20 mg daily) and then 3 months with fenofibrate (200 mg daily) with 2 months of wash-out between the two treatments." | 2.71 | Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. ( Ceska, R; Hilgertová, J; Kvasnicka, J; Skrha, J; Stulc, T; Weiserová, H, 2004) |
| "Fenofibrate treatment did not cause any change in the serum xanthine and hypoxanthine concentrations." | 2.71 | Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. ( Fuse, M; Noguchi, Y; Otsuka, Y; Saito, Y; Shibata, T; Suyama, K; Takeo, C; Tatsuno, I; Yoshida, T, 2004) |
| "Fenofibrate at 300 mg per day is effective and safe in treating Thai patients with dyslipidemia." | 2.71 | Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients. ( Chawantanpipat, C; Jeamanukulkit, N; Khanacharoen, I; Koanantakul, B; Piamsomboon, C, 2004) |
| "Only fenofibrate has significant beneficial effects on the fibrinogen levels." | 2.71 | The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. ( Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S, 2005) |
| " There were few adverse events and no rhabdomyolysis reported." | 2.71 | A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. ( Aberg, JA; Alston, BL; Brobst, SW; Evans, SR; Fichtenbaum, CJ; Glesby, MJ; Henry, WK; Owens, SI; Torriani, FJ; Yang, Y; Zackin, RA, 2005) |
| "24 patients with type 2 diabetes, who after the combined hypolipidemic treatment (pravastatin 20 mg + micronized fenofibrate 200 mg per day) cannot reach the recommended target values for long time, received for three consecutive months supplementation of 3,6 g PUFA n-3 per day or a placebo (olive oil)." | 2.71 | [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination]. ( Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2005) |
| "Fenofibrate was well tolerated during the study." | 2.70 | Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. ( Ageta, M; Sasaki, J; Yamamoto, K, 2002) |
| "Twenty-two patients with mixed hyperlipidemia participated." | 2.70 | Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. ( Ceska, R; Grauová, B; Kozich, V; Melenovský, V; Stulc, T, 2001) |
| "Cerivastatin was given in a daily dose of 0." | 2.70 | Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. ( Keber, I; Sebestjen, M; Zegura, B, 2002) |
| "A fenofibrate-induced increase of HDL-C in 20 low-HDL subjects was associated with a significant reduction of plasma sICAM-1 and sE-selectin concentrations." | 2.70 | Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. ( Calabresi, L; Dmitrieff, C; Franceschini, G; Gomaraschi, M; Omoboni, L; Villa, B, 2002) |
| "Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI)." | 2.70 | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. ( Caramelli, B; de Bernoche, CY; Monachini, MC; Santos, RD; Sartori, AM; Sposito, AC; Strabelli, T; Uip, D, 2001) |
| "As pravastatin treatment had no effect on LDL size, it is suggested that the additional effect of fenofibrate therapy on LDL size may contribute to reduce the risk of coronary heart disease (CHD) beyond what can be expected from the reduction in LDL cholesterol concentration in type IIa dyslipidemic patients." | 2.70 | A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. ( Bourgeois, J; Després, JP; Dzavik, V; Laperrière, L; Lemieux, I; Tremblay, G, 2002) |
| " The most important and commonly observed adverse effects in the fenofibrate group were dermatological events (three patients), myalgia (two patients) and asymptomatic increase in aminotransferase values (nine patients), while in the lovastatin group cardiovascular events (five patients) were the most common." | 2.69 | Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. ( Gholami, K; Maleki, M; Shafiee, A; Tavakoli, N, 1998) |
| "Atorvastatin was more effective than was micronized fenofibrate at lowering levels of total and low-density lipoprotein cholesterol, whereas fenofibrate was more effective at lowering levels of triglycerides, and raising levels of high-density lipoprotein cholesterol and apolipoprotein A1." | 2.69 | Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. ( Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Miltiadous, GA; Tsimihodimos, VK; Tzallas, CS, 1999) |
| "In combined hyperlipidemia triglycerides decreased by 45-60%, total cholesterol and LDL cholesterol by 10-12%." | 2.68 | [The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels]. ( Golubev, MA; Kalinina, AM; Mel'kina, OE; Oganov, RG; Olfer'ev, AM; Ozerova, IN; Pavlova, LI; Perova, NV, 1996) |
| "The incidence of coronary artery disease is greatly increased in those with diabetes mellitus." | 2.68 | The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. ( Steiner, G, 1996) |
| " Each patient was followed up at Out-patient Clinic regularly for diet interview, compliance and possible adverse events." | 2.68 | Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study. ( Chen, JW; Jen, SL; Lee, WL; Wang, SP, 1997) |
| " Fenofibric acid is one of the newly approved forms of fenofibrate with enhanced bioavailability and was recently approved by the Food and Drug Administation (FDA) for the treatment of various types of hyperlipidemia, in conjunction with statins." | 2.48 | Fenofibric acid for hyperlipidemia. ( Kaushik, M; Mohiuddin, SM; Saurav, A, 2012) |
| "These patients often have dyslipidemia, including low levels of HDL cholesterol and elevated levels of triglycerides and small, dense LDL." | 2.45 | Myopathy with statin-fibrate combination therapy: clinical considerations. ( Jacobson, TA, 2009) |
| "Food and Drug Administration for treatment of mixed hyperlipidemia." | 2.44 | Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia. ( Chun, P; Chung, S; Moon, YS, 2007) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Hypothyroidism is one of the common causes of the secondary hypercholesterolemia." | 2.43 | [Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature]. ( Brzosko, M; Lukjanowicz, M; Trzcińska-Butkiewicz, B, 2006) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Musculoskeletal features of hyperlipidemia are well known, although rarely encountered by rheumatologists." | 2.42 | Musculoskeletal features of disorders of lipid metabolism and multicentric reticulohistiocytosis. ( Bardin, T, 2004) |
| " Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation." | 2.41 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. ( Keating, GM; Ormrod, D, 2002) |
| "Fenofibrate is a fibric acid derivative that has been marketed since the mid-1970's (1998 in the United States)." | 2.41 | Update on fenofibrate. ( Guay, DR, 2002) |
| "Fenofibrate therapy has been associated with increases in serum aminotransferase levels, and clinical monitoring of these markers of liver function should be performed regularly." | 2.41 | Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. ( Najib, J, 2002) |
| "Fenofibrate has favorable pleiotropic effects on several features of the metabolic syndrome, which are likely to explain the clinical benefits of fibrate therapy, beyond an impact on HDL-C levels." | 2.41 | Increasing high-density lipoprotein cholesterol: an update on fenofibrate. ( Després, JP, 2001) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| " Micronised fenofibrate has improved absorption characteristics compared with the standard preparation, allowing a lower daily dosage and once-daily administration." | 2.40 | Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. ( Adkins, JC; Faulds, D, 1997) |
| "Fenofibrate is a broad spectrum lipid-lowering agent able to produce substantial reductions in plasma triglyceride and low density lipoprotein (LDL) and an increase in high density lipoprotein (HDL)." | 2.40 | Overview of fenofibrate. ( Packard, CJ, 1998) |
| "Type 2 diabetes is associated with a marked increase in the risk of coronary artery disease." | 2.40 | Diabetes, hyperlipidemia, and coronary artery disease. ( Haffner, SM, 1999) |
| "Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance." | 2.39 | Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994) |
| "Fenofibrate is a lipid-regulating drug which is structurally related to other fibric acid derivatives, such as clofibrate." | 2.38 | Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. ( Balfour, JA; Heel, RC; McTavish, D, 1990) |
| "Diagnoses included diabetic ketosis, severe hypertriglyceridemia (>225 mmol/L [>20,000 mg/dl]), lipemia retinalis, and bilateral uveitis." | 1.91 | Successful multimodal treatment of extreme hypertriglyceridemia in a juvenile diabetic dog. ( Beatty, SSK; Cagle, LA; Ehrhardt, CM; Gilor, C; Guarino, AL; Londoño, LA; Specht, AJ; Stern, JK, 2023) |
| "A fenofibrate was proposed but declined due to our patient's wish to breastfeed." | 1.72 | Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management. ( Barclay, K; Kaplan, F; Koysombat, K; Padmagirison, R, 2022) |
| "Fenofibrate dose was increased at the end of each cycle if hypertriglyceridemia persisted and adverse effects were not documented." | 1.62 | Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs. ( Gilor, C; Hulsebosch, SE; Marks, SL; Munro, MJL, 2021) |
| "Fenofibrate (FF) is a good candidate for the treatment of lipid abnormalities in patients with type 2 diabetes." | 1.56 | Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat. ( Barman, RK; Ghosh, MK; Habib, A; Khan, RI; Wahed, MII, 2020) |
| "Because the complications of hyperlipidemia are caused mainly by TC, thereby, by maintaining it at a normal level, we could set a TG target by the linear equation that allowed a certain degree of hypertriglyceridemia." | 1.56 | Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I. ( Hong, YH; Ma, MS; Qiu, ZQ; Sun, ZX; Wei, M; Xu, YW; Yuan, YH; Zhang, ZJ, 2020) |
| "The purpose of this study was to improve solubility and oral bioavailability of fenofibrate via solid dispersion (SD) using a supercritical anti-solvent (SAS) process with amphipathic polymers P407 and TPGS." | 1.51 | Improvement of the dissolution rate and bioavailability of fenofibrate by the supercritical anti-solvent process. ( Ahn, JB; Kim, DH; Lee, SE; Park, JS; Pyo, YC, 2019) |
| "Hyperlipidemia is a serious health threat that has been linked to oxidative stress and systemic inflammation, causing among many other disorders essentially liver disease." | 1.51 | Assessment of hypolipidemic, anti-inflammatory and antioxidant properties of medicinal plant Erica multiflora in triton WR-1339-induced hyperlipidemia and liver function repair in rats: A comparison with fenofibrate. ( Chekir-Ghedira, L; Dhaouefi, Z; Ghedira, K; Kalboussi, Z; Khlifi, R; Kilani-Jaziri, S; Lahmar, A; Maatouk, M, 2019) |
| "The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial found higher incidence rates of adverse reactions, including bleeding, in patients receiving the combination of extended-release niacin and laropiprant versus placebo." | 1.48 | Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. ( Gagne, JJ; Hampp, C; Houstoun, M; Marshall, JH; Reichman, ME; Toh, S, 2018) |
| "The prevalence of hyperlipidemia is increasing rapidly." | 1.48 | Coreopsis Tinctoria Modulates Lipid Metabolism by Decreasing Low-Density Lipoprotein and Improving Gut Microbiota. ( Chen, X; Cui, G; Hong, L; Li, A; Li, H; Li, Y; Liu, J; Ren, Z; Song, Y; Sun, J; Sun, R; Wulasihan, M; Yu, Z, 2018) |
| "Fenofibrate treatment reduced adiposity and attenuated obesity-induced dysfunctions of glucose metabolism in obese mice fed a high-fat diet." | 1.46 | The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice. ( Aizawa-Abe, M; Aoki, Y; Ebihara, K; Goto, T; Hirata, M; Itoh, N; Iwase, M; Jheng, HF; Kawada, T; Kim, CS; Kim, M; Li, Y; Matsuda, H; Nomura, W; Seno, S; Takahashi, H; Takahashi, N; Yu, R, 2017) |
| "Hugan Qingzhi tablets alleviates hyperlipidemia and inflammation in rats fed with high-fat diet possibly by activating AMPK pathway and suppress NF-αB activity to arrest the progression of nonalcoholic fatty liver disease." | 1.46 | [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease]. ( Tang, WJ; Xia, F; Yao, XR; Zhou, BJ, 2017) |
| "AF-LIP may be beneficial for the treatment of atherosclerosis, since atherosclerosis is one of the secondary complications of hyperlipidemia." | 1.40 | Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models. ( Ashok, P; Poulose, DN; Singh, D; Suresh, B, 2014) |
| "Andrographolide (1) has been identified as one of the active constituents against atherosclerosis." | 1.39 | Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity. ( Bhatia, G; Pandeti, S; Shukla, A; Sonkar, R; Tadigoppula, N, 2013) |
| "Fenofibrate lipospheres were prepared by the melt dispersion technique." | 1.39 | Formulation and optimization of fenofibrate lipospheres using Taguchi's experimental design. ( Lakshmi, PK; Saroja, C, 2013) |
| "Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia." | 1.39 | Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture. ( Jia, ZH; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, Q; Yu, ZL; Zhang, Y; Zhu, PL, 2013) |
| " Adverse event (AE) profiles of FF/PRA 160 mg/40 mg (n=645 in the double-blind cohort) were evaluated relative to comparators (statins, n=519 or fenofibrate, n=122)." | 1.38 | Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. ( Bryniarski, L; Császár, A; De Niet, S; Ducobu, J; Farnier, M; Marcereuil, D; Retterstøl, K; Steinmetz, A; Vanderbist, F, 2012) |
| "Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease." | 1.36 | LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. ( Phillips, W; Schaefer, S, 2010) |
| "Fenofibrate treatment decreased TAG and cholesterol concentrations in plasma, total lipids of the whole body and liver, and EPA and DHA contents in tissues." | 1.35 | Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp ( Ctenopharyngodon idella) fed a high-fat diet. ( Clouet, P; Degrace, P; Du, ZY; Frøyland, L; Liu, YJ; Tian, LX; Zheng, WH, 2008) |
| "Primary hypothyroidism and type 2 diabetes are both typically associated with the increased level of triglycerides." | 1.33 | A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas. ( Chang, SH; Chung, SI; Hahm, JR; Jung, JH; Jung, TS; Kim, DR; Kim, MA; Lee, GW; Park, JR; Park, KJ, 2005) |
| "A total of 16 young (2-month-old) and 16 old rats (24-month-old) were randomly assigned to a control group and fenofibrate group (fenofibrate in a total therapeutic dosage of 0." | 1.33 | Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia. ( Wang, ZJ; Ye, P; Zhang, XJ; Zhao, YL, 2005) |
| "Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis." | 1.33 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. ( Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006) |
| "Totally 147 patients with hyperlipidemia [72 men mean age: (56." | 1.33 | [Effect of polymorphism of human intestinal fatty acid binding protein gene on the therapeutic efficacy of fenofibrate]. ( Chang, XT; Dong, MG; Du, X; Hou, LJ; Liu, J; Wang, J; Wang, ZH; Zhou, JG, 2006) |
| "Treatment with fenofibrate (200 mg qd), however, was followed by a significant reduction of triglyceride and cholesterol concentrations to 12 mmol/L (1050 mg/dL) and 10 mmol/L (387 mg/dL)." | 1.32 | [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia]. ( Battegay, M; Hirsch, HH, 2003) |
| "Fibrates are widely used for treatment of hyperlipidemia." | 1.32 | A patient with hyperlipidemia who had a gallbladder stone caused by administration of fenofibrate. ( Egashira, T; Inuzuka, S; Kinoshita, J; Kumamoto, M; Sata, M; Shishido, S; Tomiyasu, N; Ueno, T, 2003) |
| "This model of hyperlipidemia has been modified to produce dyslipidedmia with diabetes complexities by feeding with high fat diet added with 9% (w/w) fructose." | 1.32 | In vivo model for dyslipidemia with diabetes mellitus in hamster. ( Bhatia, G; Chander, R; Khanna, AK; Puri, A; Rastogi, AK; Rizvi, F; Saxena, R; Wulff, EM, 2003) |
| "In patients with mixed hyperlipidemia, monotherapy with one of these agents may not be effective and combined treatment may be preferable." | 1.32 | Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia. ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Kłosiewicz-Latoszek, L; Stolarska, I; Szostak, WB; Wiśniewska, B, 2004) |
| "In patients with type IIa or IIb dyslipidemia, TC decreased (-14." | 1.31 | Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. ( Callaghan, DJ; Ramjattan, BR; Theiss, U, 2002) |
| "Fenofibrate treatment also caused the attenuation of impairment of endothelium-dependent relaxation by the oxidized LDL from these patients." | 1.31 | The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients. ( Arthur, G; Choy, PC; Dembinski, T; Hatch, GM; Kroeger, EA; Liang, B; Man, RY; McMaster, JC; Mymin, D; Shen, G, 2000) |
| "The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes." | 1.31 | Status report of lipid-lowering trials in diabetes. ( Armitage, J; Betteridge, DJ; Colhoun, H, 2000) |
| "Twenty patients with uncomplicated hyperlipidemia but no atherosclerosis, 20 patients with hyperlipidemia plus clear atherosclerosis, and 40 matched controls were studied." | 1.31 | Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. ( Belgore, FM; Blann, AD; Conri, C; Constans, J; Lip, GY, 2001) |
| "Fenofibrate was the probable cause of elevations in serum creatinine concentrations in six patients at our clinic." | 1.31 | Fenofibrate-Induced elevation in serum creatinine. ( Nabulsi, S; Ritter, JL, 2001) |
| "Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia." | 1.31 | Effects of fenofibrate on lipid parameters in obese rhesus monkeys. ( Bodkin, NL; Brown, HR; Brown, PJ; Hansen, BC; Kliewer, SA; Lehmann, JM; Lewis, MC; Ott, RJ; Plunket, KD; Tong, WQ; Way, JM; Wilkison, WO; Winegar, DA, 2001) |
| "The treatment of fenofibrate (30 mg." | 1.31 | Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. ( Kashiwagi, A; Kikkawa, R; Maegawa, H; Nagai, Y; Nakamura, T; Nishio, Y, 2002) |
| "Fenofibrate treatment resulted in decreases in total cholesterol, triglycerides (TG), and VLDL cholesterol of 19%, 48%, and 70%, respectively, and a 28% increase in HDL cholesterol, with no significant change in the proportion of Lp A-I and Lp A-I/A-II particles." | 1.29 | Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. ( Agnani, G; Edgar, AD; Fruchart, JC; Lau, P; Marcel, YL; McPherson, R, 1996) |
| "ml-1), Cmax (812 ng." | 1.28 | Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ( Bizollon, CA; Boissonnat, P; deLorgeril, M; Dureau, G; Faucon, G; Guichard, JP; Guidollet, J; Levy-Prades-Sauron, R; Renaud, S, 1992) |
| "Fenofibrate subdoses were applied as an adjuvant therapy in 64 women for improving lipid metabolism." | 1.28 | Protective role of lipanthyl in women taking oral contraceptives. ( Sásdi, A, 1991) |
| "In patients with heterozygous familial hypercholesterolemia (FH), bezafibrate (n = 5) and fenofibrate (n = 7) produced a similar significant reduction of total cholesterol, LDL-cholesterol, and triglycerides by 21, 23, and 32%, respectively." | 1.27 | Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. ( Leiss, O; Meyer-Krahmer, K; von Bergmann, K, 1986) |
| " Under the same experimental conditions clofibrate presents a poor dose-response correlation on plasma lipids and generally appears at least 10 times less active than LR 19731 on cholesterol but more effective on liver weight." | 1.26 | Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731). ( Fregnan, GB; Frigerio, L; Porta, R, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (7.47) | 18.7374 |
| 1990's | 43 (13.96) | 18.2507 |
| 2000's | 170 (55.19) | 29.6817 |
| 2010's | 57 (18.51) | 24.3611 |
| 2020's | 15 (4.87) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 2 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Mueller, R | 1 |
| Yang, J | 1 |
| Duan, C | 1 |
| Pop, E | 1 |
| Geoffroy, OJ | 1 |
| Zhang, LH | 1 |
| Huang, TB | 1 |
| Denisenko, S | 1 |
| McCosar, BH | 1 |
| Oniciu, DC | 1 |
| Bisgaier, CL | 1 |
| Pape, ME | 1 |
| Freiman, CD | 1 |
| Goetz, B | 1 |
| Cramer, CT | 1 |
| Hopson, KL | 1 |
| Dasseux, JL | 1 |
| Shi, GQ | 1 |
| Dropinski, JF | 1 |
| Zhang, Y | 4 |
| Santini, C | 1 |
| Sahoo, SP | 1 |
| Berger, JP | 1 |
| Macnaul, KL | 1 |
| Zhou, G | 1 |
| Agrawal, A | 1 |
| Alvaro, R | 1 |
| Cai, TQ | 1 |
| Hernandez, M | 1 |
| Wright, SD | 2 |
| Moller, DE | 1 |
| Heck, JV | 1 |
| Meinke, PT | 1 |
| Rudolph, J | 1 |
| Chen, L | 1 |
| Majumdar, D | 1 |
| Bullock, WH | 1 |
| Burns, M | 1 |
| Claus, T | 1 |
| Dela Cruz, FE | 1 |
| Daly, M | 1 |
| Ehrgott, FJ | 1 |
| Johnson, JS | 1 |
| Livingston, JN | 1 |
| Schoenleber, RW | 1 |
| Shapiro, J | 1 |
| Yang, L | 1 |
| Tsutsumi, M | 1 |
| Ma, X | 1 |
| Mokale, SN | 2 |
| Elgire, RD | 1 |
| Sakle, N | 1 |
| Shinde, DB | 1 |
| Sashidhara, KV | 2 |
| Kumar, M | 1 |
| Sonkar, R | 3 |
| Singh, BS | 1 |
| Khanna, AK | 3 |
| Bhatia, G | 5 |
| Patel, HM | 1 |
| Noolvi, MN | 1 |
| Goyal, A | 1 |
| Thippeswamy, BS | 1 |
| Pandeti, S | 1 |
| Shukla, A | 1 |
| Tadigoppula, N | 1 |
| Nevase, MC | 1 |
| Sakle, NS | 1 |
| Dube, PN | 1 |
| Shelke, VR | 1 |
| Bhavale, SA | 1 |
| Begum, A | 1 |
| Dodda, RP | 1 |
| Palnati, GR | 1 |
| Chen, ZZ | 1 |
| Xie, YD | 2 |
| Shao, LH | 1 |
| Wang, QT | 1 |
| Xu, YH | 2 |
| Bian, XL | 2 |
| Liu, JP | 1 |
| Wang, B | 1 |
| Shi, YH | 1 |
| Wang, W | 2 |
| Wang, XP | 1 |
| Sun, M | 2 |
| Xu, XY | 1 |
| Zhang, X | 1 |
| Chen, Y | 1 |
| Tong, N | 1 |
| Shao, Q | 1 |
| Zhou, Y | 1 |
| Mu, T | 1 |
| Yang, X | 1 |
| Teoh, CS | 1 |
| Yuen, YS | 1 |
| Rodriguez-Gutierrez, R | 1 |
| González, JG | 1 |
| Parmar, D | 1 |
| Shaikh, F | 1 |
| Cruz-López, P | 1 |
| Barclay, K | 1 |
| Koysombat, K | 1 |
| Padmagirison, R | 1 |
| Kaplan, F | 1 |
| du Toit, LC | 1 |
| Hulisani Demana, P | 1 |
| Essop Choonara, Y | 1 |
| Guarino, AL | 1 |
| Cagle, LA | 1 |
| Ehrhardt, CM | 1 |
| Beatty, SSK | 1 |
| Stern, JK | 1 |
| Gilor, C | 2 |
| Specht, AJ | 1 |
| Londoño, LA | 1 |
| Jin, L | 1 |
| Hua, H | 1 |
| Ji, Y | 1 |
| Jia, Z | 1 |
| Peng, M | 1 |
| Huang, S | 1 |
| Lee, J | 1 |
| Jeon, S | 1 |
| Lee, M | 1 |
| Yoon, M | 1 |
| Zhang, YH | 1 |
| Liu, B | 1 |
| Meng, Q | 1 |
| Zhang, D | 2 |
| Yang, H | 1 |
| Li, G | 1 |
| Wang, Y | 3 |
| Zhou, H | 1 |
| Xu, ZX | 1 |
| Lizunov, AV | 2 |
| Okunevich, IV | 2 |
| Orlov, SV | 1 |
| Lebedev, AA | 2 |
| Bychkov, ER | 2 |
| Piotrovskiy, LB | 2 |
| Shabanov, PD | 2 |
| Ghosh, MK | 1 |
| Wahed, MII | 1 |
| Khan, RI | 1 |
| Habib, A | 2 |
| Barman, RK | 1 |
| Zhang, ZJ | 1 |
| Yuan, YH | 1 |
| Ma, MS | 1 |
| Hong, YH | 1 |
| Sun, ZX | 1 |
| Xu, YW | 1 |
| Wei, M | 1 |
| Qiu, ZQ | 1 |
| Munro, MJL | 1 |
| Hulsebosch, SE | 1 |
| Marks, SL | 1 |
| Knapik-Kowalczuk, J | 1 |
| Kramarczyk, D | 1 |
| Jurkiewicz, K | 1 |
| Chmiel, K | 1 |
| Paluch, M | 1 |
| Goto, T | 1 |
| Hirata, M | 1 |
| Aoki, Y | 1 |
| Iwase, M | 1 |
| Takahashi, H | 1 |
| Kim, M | 1 |
| Li, Y | 2 |
| Jheng, HF | 1 |
| Nomura, W | 1 |
| Takahashi, N | 1 |
| Kim, CS | 1 |
| Yu, R | 1 |
| Seno, S | 1 |
| Matsuda, H | 1 |
| Aizawa-Abe, M | 1 |
| Ebihara, K | 1 |
| Itoh, N | 1 |
| Kawada, T | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Chen, K | 1 |
| Wang, CQ | 1 |
| Fan, YQ | 1 |
| Xie, YS | 1 |
| Yin, ZF | 1 |
| Xu, ZJ | 1 |
| Zhang, HL | 1 |
| Cao, JT | 1 |
| Gao, L | 1 |
| Gagne, JJ | 1 |
| Houstoun, M | 1 |
| Reichman, ME | 1 |
| Hampp, C | 1 |
| Marshall, JH | 1 |
| Toh, S | 1 |
| Furue, K | 1 |
| Mitoma, C | 1 |
| Tsuji, G | 1 |
| Furue, M | 1 |
| Ren, Z | 1 |
| Liu, J | 2 |
| Li, H | 1 |
| Li, A | 1 |
| Hong, L | 1 |
| Cui, G | 1 |
| Sun, R | 1 |
| Wulasihan, M | 1 |
| Sun, J | 1 |
| Song, Y | 1 |
| Yu, Z | 1 |
| Chen, X | 1 |
| Garg, G | 1 |
| Patil, A | 1 |
| Singh, J | 1 |
| Kaushik, N | 1 |
| Praksah, A | 1 |
| Pal, A | 1 |
| Chakrabarti, A | 1 |
| Hu, T | 1 |
| Lin, M | 1 |
| Li, M | 1 |
| Zhang, J | 2 |
| Vukšić, A | 1 |
| Lovrić, J | 1 |
| Konjevoda, P | 1 |
| Blažević, N | 1 |
| Bilušić, M | 1 |
| Bradamante, V | 1 |
| Ahn, JB | 1 |
| Kim, DH | 1 |
| Lee, SE | 1 |
| Pyo, YC | 1 |
| Park, JS | 1 |
| Khlifi, R | 1 |
| Lahmar, A | 1 |
| Dhaouefi, Z | 1 |
| Kalboussi, Z | 1 |
| Maatouk, M | 1 |
| Kilani-Jaziri, S | 1 |
| Ghedira, K | 1 |
| Chekir-Ghedira, L | 1 |
| Saroja, C | 1 |
| Lakshmi, PK | 1 |
| Pan, SY | 1 |
| Jia, ZH | 1 |
| Yu, Q | 1 |
| Wang, XY | 1 |
| Sun, N | 1 |
| Zhu, PL | 1 |
| Yu, ZL | 1 |
| Ko, KM | 1 |
| Le, NA | 1 |
| Farkas-Epperson, M | 1 |
| Sweeney, ME | 1 |
| Wilson, PW | 1 |
| Virgil Brown, W | 1 |
| Rull, A | 1 |
| Geeraert, B | 1 |
| Aragonès, G | 1 |
| Beltrán-Debón, R | 1 |
| Rodríguez-Gallego, E | 1 |
| García-Heredia, A | 1 |
| Pedro-Botet, J | 2 |
| Joven, J | 1 |
| Holvoet, P | 1 |
| Camps, J | 1 |
| Kuno, T | 1 |
| Hata, K | 1 |
| Takamatsu, M | 1 |
| Hara, A | 1 |
| Hirose, Y | 1 |
| Takahashi, S | 1 |
| Imaida, K | 1 |
| Tanaka, T | 1 |
| Ashok, P | 1 |
| Singh, D | 1 |
| Poulose, DN | 1 |
| Suresh, B | 1 |
| Chahande, S | 1 |
| Murthy, R | 1 |
| Xu, QY | 1 |
| Liu, YH | 1 |
| Zhang, Q | 1 |
| Ma, B | 1 |
| Yang, ZD | 1 |
| Liu, L | 1 |
| Yao, D | 1 |
| Cui, GB | 1 |
| Sun, JJ | 1 |
| Wu, ZM | 1 |
| Kusunoki, M | 1 |
| Sato, D | 1 |
| Tsutsumi, K | 1 |
| Tsutsui, H | 1 |
| Nakamura, T | 2 |
| Oshida, Y | 1 |
| Shih, CC | 1 |
| Wu, JB | 1 |
| Jian, JY | 1 |
| Lin, CH | 1 |
| Ho, HY | 1 |
| Modjtahedi, BS | 1 |
| Bose, N | 1 |
| Papakostas, TD | 1 |
| Morse, L | 1 |
| Vavvas, DG | 1 |
| Kishan, AU | 1 |
| Oikawa, S | 1 |
| Yamashita, S | 1 |
| Nakaya, N | 1 |
| Sasaki, J | 2 |
| Kono, S | 1 |
| Yao, XR | 1 |
| Xia, F | 1 |
| Tang, WJ | 1 |
| Zhou, BJ | 1 |
| Farnier, M | 13 |
| Perevozskaya, I | 4 |
| Taggart, WV | 1 |
| Kush, D | 2 |
| Mitchel, YB | 3 |
| Filippatos, T | 1 |
| Milionis, HJ | 3 |
| Robinson, JG | 1 |
| Jones, PH | 1 |
| Srivastava, RA | 3 |
| Cetinkaya, R | 1 |
| Uyanik, A | 1 |
| Yildirim, R | 1 |
| Bilen, Y | 1 |
| Keles, M | 1 |
| Lai, MY | 1 |
| Lin, CC | 1 |
| Chung, SL | 1 |
| Wu, CH | 1 |
| Yang, WC | 1 |
| Tseng, YT | 1 |
| Rajamani, K | 1 |
| Colman, PG | 1 |
| Li, LP | 1 |
| Best, JD | 2 |
| Voysey, M | 1 |
| D'Emden, MC | 1 |
| Laakso, M | 2 |
| Baker, JR | 1 |
| Keech, AC | 2 |
| Jacobson, TA | 1 |
| Abourbih, S | 1 |
| Filion, KB | 1 |
| Joseph, L | 1 |
| Schiffrin, EL | 1 |
| Rinfret, S | 1 |
| Poirier, P | 1 |
| Pilote, L | 1 |
| Genest, J | 1 |
| Eisenberg, MJ | 1 |
| Burgess, DC | 1 |
| Hunt, D | 1 |
| Li, L | 1 |
| Zannino, D | 1 |
| Williamson, E | 1 |
| Davis, TM | 1 |
| Kesäniemi, YA | 1 |
| Sy, RW | 1 |
| Lehto, S | 1 |
| Mann, S | 1 |
| Li, LJ | 1 |
| Chen, H | 1 |
| Ren, JY | 1 |
| Wang, L | 1 |
| Luo, Y | 1 |
| Phillips, W | 1 |
| Schaefer, S | 1 |
| Whitfield, LR | 1 |
| Porcari, AR | 1 |
| Alvey, C | 1 |
| Abel, R | 1 |
| Bullen, W | 1 |
| Hartman, D | 1 |
| Maeda, T | 1 |
| Oyama, J | 1 |
| Higuchi, Y | 1 |
| Koyanagi, M | 1 |
| Sasaki, M | 1 |
| Arima, T | 1 |
| Mimori, K | 1 |
| Makino, N | 1 |
| Irvin, MR | 1 |
| Kabagambe, EK | 1 |
| Tiwari, HK | 1 |
| Parnell, LD | 2 |
| Straka, RJ | 2 |
| Tsai, M | 1 |
| Ordovas, JM | 2 |
| Arnett, DK | 2 |
| He, S | 1 |
| Ducobu, J | 4 |
| Bryniarski, L | 3 |
| Agouridis, AP | 1 |
| Filippatos, TD | 1 |
| Derdemezis, CS | 1 |
| Mikhailidis, DP | 2 |
| Elisaf, MS | 7 |
| Zhou, JY | 1 |
| Zhou, SW | 1 |
| Ruchala, M | 1 |
| Szczepanek, E | 1 |
| Puszczewicz, M | 1 |
| Sosnowski, P | 1 |
| Sowinski, J | 1 |
| Steinmetz, A | 3 |
| Retterstøl, K | 3 |
| Császár, A | 4 |
| Sunil, C | 1 |
| Ignacimuthu, S | 1 |
| Kumarappan, C | 1 |
| Li, W | 1 |
| Jia, HY | 1 |
| He, XH | 1 |
| Shi, WG | 1 |
| Zhong, BH | 1 |
| Lee, SH | 1 |
| Cho, KI | 1 |
| Kim, JY | 1 |
| Ahn, YK | 1 |
| Rha, SW | 1 |
| Kim, YJ | 1 |
| Choi, YS | 1 |
| Choi, SW | 1 |
| Jeon, DW | 1 |
| Min, PK | 1 |
| Choi, DJ | 1 |
| Baek, SH | 1 |
| Kim, KS | 1 |
| Byun, YS | 1 |
| Jang, Y | 1 |
| Marcereuil, D | 1 |
| De Niet, S | 1 |
| Vanderbist, F | 1 |
| Saurav, A | 1 |
| Kaushik, M | 1 |
| Mohiuddin, SM | 1 |
| Sisková, K | 1 |
| Bilka, F | 1 |
| Adameová, A | 1 |
| Balazová, A | 1 |
| Mydla, M | 1 |
| Pauliková, I | 1 |
| Samra, M | 1 |
| Abcar, AC | 1 |
| Ncube, V | 1 |
| Starkey, B | 1 |
| Wang, T | 1 |
| Reyes-Soffer, G | 1 |
| Ngai, CI | 1 |
| Lovato, L | 1 |
| Karmally, W | 1 |
| Ramakrishnan, R | 1 |
| Holleran, S | 1 |
| Ginsberg, HN | 2 |
| Ramjattan, BR | 1 |
| Callaghan, DJ | 1 |
| Theiss, U | 1 |
| le Roux, CW | 1 |
| Murphy, E | 1 |
| Seed, M | 1 |
| Ganotakis, E | 1 |
| Tsimihodimos, V | 3 |
| Bairaktari, E | 4 |
| Rizos, E | 1 |
| Athyros, V | 1 |
| Seferiades, C | 1 |
| Elisaf, M | 4 |
| Keating, GM | 1 |
| Ormrod, D | 2 |
| Hottelart, C | 1 |
| El Esper, N | 1 |
| Rose, F | 1 |
| Achard, JM | 1 |
| Fournier, A | 1 |
| Márk, L | 1 |
| Hodgson, JM | 1 |
| Watts, GF | 2 |
| Playford, DA | 2 |
| Burke, V | 2 |
| Croft, KD | 1 |
| Forcheron, F | 1 |
| Cachefo, A | 1 |
| Thevenon, S | 1 |
| Pinteur, C | 1 |
| Beylot, M | 1 |
| Yamamoto, K | 1 |
| Ageta, M | 1 |
| Corbelli, JC | 1 |
| Bullano, MF | 1 |
| Willey, VJ | 1 |
| Cziraky, MJ | 1 |
| Corbelli, ME | 1 |
| Waugh, W | 1 |
| Guay, DR | 2 |
| Cavallero, E | 1 |
| Dachet, C | 1 |
| Assadolahi, F | 1 |
| Martin, C | 1 |
| Navarro, N | 1 |
| Ansquer, JC | 2 |
| Corda, C | 1 |
| Foucher, C | 2 |
| Juhan-Vague, I | 1 |
| Jacotot, B | 1 |
| Ceska, R | 6 |
| Stulc, T | 5 |
| Zima, T | 1 |
| Malbohan, I | 1 |
| Fialova, L | 1 |
| Packard, KA | 1 |
| Backes, JM | 1 |
| Lenz, TL | 1 |
| Wurdeman, RL | 1 |
| Destache, C | 1 |
| Hilleman, DE | 1 |
| VanHaelst, L | 1 |
| Salomon, H | 3 |
| Hayakawa, T | 1 |
| Shimoyama, K | 1 |
| Sekiya, S | 1 |
| Sekiguchi, M | 1 |
| Inotsume, N | 1 |
| Bortolini, M | 1 |
| Salko, T | 2 |
| Freudenreich, MO | 1 |
| Isaacsohn, JL | 2 |
| Troendle, AJ | 2 |
| Gonasun, L | 2 |
| Najib, J | 2 |
| Hepburn, AL | 1 |
| Kaye, SA | 1 |
| Feher, MD | 1 |
| Kakafika, A | 2 |
| Tambaki, AP | 1 |
| Chapman, MJ | 2 |
| Tselepis, AD | 1 |
| Vega, GL | 2 |
| Ma, PT | 1 |
| Cater, NB | 2 |
| Filipchuk, N | 1 |
| Meguro, S | 2 |
| Garcia-Garcia, AB | 1 |
| Grundy, SM | 3 |
| Hirsch, HH | 1 |
| Battegay, M | 1 |
| Telford, M | 1 |
| Rizvi, F | 2 |
| Puri, A | 2 |
| Wulff, EM | 2 |
| Rastogi, AK | 2 |
| Chander, R | 2 |
| Kowalski, J | 3 |
| Okopień, B | 4 |
| Madej, A | 2 |
| Zieliński, M | 2 |
| Belowski, D | 3 |
| Kalina, Z | 2 |
| Herman, ZS | 3 |
| Devroey, D | 1 |
| Velkeniers, B | 1 |
| Duquet, W | 1 |
| Betz, W | 1 |
| Melenovsky, V | 3 |
| Kozich, V | 2 |
| Grauova, B | 2 |
| Krijt, J | 1 |
| Wichterle, D | 2 |
| Haas, T | 2 |
| Malik, J | 2 |
| Hradec, J | 2 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 2 |
| Błaszczyk, J | 2 |
| Olejniczak, J | 2 |
| Kowalski, M | 2 |
| Błaszczyk-Suszyńska, J | 2 |
| Petecka, E | 2 |
| Kedziora, J | 2 |
| Gburek, J | 1 |
| Zhu, J | 1 |
| Ye, P | 2 |
| Tuomilehto, J | 2 |
| Barker, BJ | 1 |
| Goodenough, RR | 1 |
| Sarano, NE | 1 |
| Kozlov, SG | 1 |
| Tvorogova, MG | 1 |
| Liakishev, AA | 1 |
| Naumov, VG | 1 |
| Meikle, AW | 1 |
| Findling, J | 1 |
| Kushnir, MM | 1 |
| Rockwood, AL | 1 |
| Nelson, GJ | 1 |
| Terry, AH | 1 |
| Papakostas, J | 1 |
| Chasiotis, G | 1 |
| Seferiadis, K | 1 |
| Hadizadeh, DR | 1 |
| Inuzuka, S | 1 |
| Tomiyasu, N | 1 |
| Kumamoto, M | 1 |
| Egashira, T | 1 |
| Kinoshita, J | 1 |
| Shishido, S | 1 |
| Sata, M | 1 |
| Ueno, T | 1 |
| Dejager, S | 1 |
| Bilz, S | 1 |
| Wagner, S | 1 |
| Schmitz, M | 1 |
| Bedynek, A | 1 |
| Keller, U | 1 |
| Demant, T | 1 |
| de Luis, DA | 3 |
| Bachiller, P | 2 |
| Aller, R | 3 |
| Eiros Bouza, J | 1 |
| Izaola, O | 1 |
| Lemieux, I | 3 |
| Després, JP | 4 |
| Kłosiewicz-Latoszek, L | 2 |
| Respondek, W | 1 |
| Białobrzeska-Paluszkiewicz, J | 2 |
| Grzybowska, B | 2 |
| Jakóbisiak-Ostasz, B | 1 |
| Stolarska, I | 2 |
| Bardin, T | 1 |
| Sharpe, M | 1 |
| Jarvis, B | 1 |
| Dierkes, J | 3 |
| Westphal, S | 3 |
| Luley, C | 3 |
| Durrington, PN | 1 |
| Hamann, A | 1 |
| Kallend, D | 1 |
| Smith, K | 1 |
| Martens-Lobenhoffer, J | 1 |
| Bode-Böger, SM | 1 |
| Wysocki, J | 1 |
| Kalina, M | 1 |
| Kochanski, L | 1 |
| Winkler, K | 1 |
| Weltzien, P | 1 |
| Friedrich, I | 1 |
| Schmitz, H | 1 |
| Nickell, HH | 1 |
| Hauck, P | 1 |
| Hoffmann, MM | 1 |
| Baumstark, MW | 1 |
| Wieland, H | 1 |
| März, W | 1 |
| Skrha, J | 1 |
| Hilgertová, J | 1 |
| Weiserová, H | 1 |
| Kvasnicka, J | 1 |
| Ghosh, B | 1 |
| Sengupta, S | 1 |
| Bhattacharjee, B | 1 |
| Majumder, A | 1 |
| Sarkar, SB | 1 |
| Saxena, R | 1 |
| Szostak, WB | 1 |
| Wiśniewska, B | 1 |
| Ascaso, JF | 1 |
| Fernández-Cruz, A | 1 |
| González Santos, P | 1 |
| Hernández Mijares, A | 1 |
| Mangas Rojas, A | 1 |
| Millán, J | 1 |
| Felipe Pallardo, L | 1 |
| Pérez-Jiménez, F | 1 |
| Pía, G | 1 |
| Pintó, X | 1 |
| Plaza, I | 1 |
| Rubiés-Prat, J | 1 |
| Koh, KK | 1 |
| Ahn, JY | 1 |
| Jin, DK | 1 |
| Han, SH | 1 |
| Kim, HS | 1 |
| Choi, IS | 1 |
| Ahn, TH | 1 |
| Shin, EK | 1 |
| Jeong, EM | 1 |
| Alsheikh-Ali, AA | 1 |
| Kuvin, JT | 1 |
| Karas, RH | 1 |
| Dobordzhginidze, LM | 1 |
| Sebestjen, M | 2 |
| Keber, I | 2 |
| Zegura, B | 2 |
| Simcic, S | 1 |
| Bozic, M | 1 |
| Fressart, MM | 1 |
| Stegnar, M | 1 |
| Sulcová, J | 1 |
| Hill, M | 1 |
| Hampl, R | 1 |
| Masek, Z | 1 |
| Vondra, K | 1 |
| Coban, E | 2 |
| Sari, R | 2 |
| Derosa, G | 1 |
| Cicero, AE | 1 |
| Bertone, G | 1 |
| Piccinni, MN | 1 |
| Ciccarelli, L | 1 |
| Roggeri, DE | 1 |
| Duez, H | 1 |
| Lefebvre, B | 1 |
| Poulain, P | 1 |
| Torra, IP | 2 |
| Percevault, F | 1 |
| Luc, G | 1 |
| Peters, JM | 1 |
| Gonzalez, FJ | 1 |
| Gineste, R | 1 |
| Helleboid, S | 1 |
| Dzavik, V | 2 |
| Fruchart, JC | 4 |
| Fiévet, C | 1 |
| Lefebvre, P | 1 |
| Staels, B | 3 |
| Noguchi, Y | 1 |
| Tatsuno, I | 1 |
| Suyama, K | 1 |
| Shibata, T | 1 |
| Yoshida, T | 1 |
| Otsuka, Y | 1 |
| Fuse, M | 1 |
| Takeo, C | 1 |
| Saito, Y | 1 |
| Huzarska, M | 1 |
| Kulach, A | 1 |
| Stachura-Kulach, A | 1 |
| Rattier, S | 1 |
| Taskinen, MR | 2 |
| Steiner, G | 3 |
| Krysiak, R | 1 |
| Haberka, M | 1 |
| Freeman, MW | 1 |
| Macdonell, G | 3 |
| Davies, MJ | 3 |
| Gumbiner, B | 2 |
| Stalenhoef, AF | 1 |
| Koanantakul, B | 2 |
| Jeamanukulkit, N | 1 |
| Piamsomboon, C | 1 |
| Chawantanpipat, C | 1 |
| Khanacharoen, I | 1 |
| Reifel-Miller, A | 1 |
| Otto, K | 1 |
| Hawkins, E | 1 |
| Barr, R | 1 |
| Bensch, WR | 1 |
| Bull, C | 1 |
| Dana, S | 1 |
| Klausing, K | 1 |
| Martin, JA | 1 |
| Rafaeloff-Phail, R | 1 |
| Rafizadeh-Montrose, C | 1 |
| Rhodes, G | 1 |
| Robey, R | 1 |
| Rojo, I | 1 |
| Rungta, D | 1 |
| Snyder, D | 1 |
| Wilbur, K | 1 |
| Zhang, T | 1 |
| Zink, R | 1 |
| Warshawsky, A | 1 |
| Brozinick, JT | 1 |
| Ozdogan, M | 1 |
| Yazicioglu, G | 1 |
| Jacob, SS | 1 |
| Jacob, S | 1 |
| Williams, C | 1 |
| Deeg, MA | 1 |
| Saklamaz, A | 1 |
| Comlekci, A | 1 |
| Temiz, A | 1 |
| Caliskan, S | 1 |
| Ceylan, C | 1 |
| Alacacioglu, A | 1 |
| Yesil, S | 1 |
| Park, JR | 1 |
| Jung, TS | 1 |
| Jung, JH | 1 |
| Lee, GW | 1 |
| Kim, MA | 1 |
| Park, KJ | 1 |
| Kim, DR | 1 |
| Chang, SH | 1 |
| Chung, SI | 1 |
| Hahm, JR | 1 |
| Athyros, VG | 2 |
| Papageorgiou, AA | 2 |
| Didangelos, TP | 1 |
| Peletidou, A | 1 |
| Kleta, D | 1 |
| Karagiannis, A | 1 |
| Kakafika, AI | 1 |
| Tziomalos, K | 1 |
| Wang, ZJ | 1 |
| Zhang, XJ | 1 |
| Zhao, YL | 1 |
| Borja, J | 1 |
| Choi, JH | 1 |
| Shin, YL | 1 |
| Kim, GH | 1 |
| Hong, SJ | 1 |
| Yoo, HW | 1 |
| Aberg, JA | 1 |
| Zackin, RA | 1 |
| Brobst, SW | 1 |
| Evans, SR | 1 |
| Alston, BL | 1 |
| Henry, WK | 1 |
| Glesby, MJ | 1 |
| Torriani, FJ | 1 |
| Yang, Y | 1 |
| Owens, SI | 1 |
| Fichtenbaum, CJ | 1 |
| Zeman, M | 2 |
| Zák, A | 2 |
| Vecka, M | 2 |
| Tvrzická, E | 2 |
| Písaríková, A | 1 |
| Stanková, B | 2 |
| Erol, A | 1 |
| Shiri-Sverdlov, R | 1 |
| Wouters, K | 1 |
| van Gorp, PJ | 1 |
| Gijbels, MJ | 1 |
| Noel, B | 1 |
| Buffat, L | 1 |
| Maeda, N | 1 |
| van Bilsen, M | 1 |
| Hofker, MH | 2 |
| Jublanc, C | 1 |
| Giral, P | 1 |
| Turpin, G | 1 |
| Asano, A | 1 |
| Kobayashi, J | 1 |
| Murase, Y | 1 |
| Nohara, A | 1 |
| Kawashiri, MA | 1 |
| Inazu, A | 1 |
| Shimizu, M | 1 |
| Mabuchi, H | 1 |
| Bloomfield, HE | 1 |
| Trivedi, NR | 1 |
| Cong, Z | 1 |
| Nelson, AM | 1 |
| Albert, AJ | 1 |
| Rosamilia, LL | 1 |
| Sivarajah, S | 1 |
| Gilliland, KL | 1 |
| Liu, W | 1 |
| Mauger, DT | 1 |
| Gabbay, RA | 1 |
| Thiboutot, DM | 1 |
| Chang, XT | 1 |
| Wang, ZH | 1 |
| Du, X | 1 |
| Dong, MG | 1 |
| Hou, LJ | 1 |
| Wang, J | 1 |
| Zhou, JG | 1 |
| Iovine, C | 1 |
| Lilli, S | 1 |
| Gentile, A | 1 |
| Patti, L | 1 |
| Di Marino, L | 1 |
| Cipriano, P | 1 |
| Riccardi, G | 1 |
| Rivellese, AA | 1 |
| Samson, SL | 1 |
| Pownall, HJ | 1 |
| Scott, LW | 1 |
| Ballantyne, CM | 1 |
| Smith, EO | 1 |
| Sekhar, RV | 1 |
| Balasubramanyam, A | 1 |
| Zhu, S | 1 |
| Su, G | 1 |
| Meng, QH | 1 |
| Amrani, S | 1 |
| Harnafi, H | 1 |
| Bouanani, Nel H | 1 |
| Aziz, M | 1 |
| Caid, HS | 1 |
| Manfredini, S | 1 |
| Besco, E | 1 |
| Napolitano, M | 1 |
| Bravo, E | 1 |
| Keech, A | 1 |
| Simes, J | 1 |
| Barter, P | 1 |
| Best, J | 1 |
| Scott, R | 1 |
| Roth, E | 1 |
| Gil-Extremera, B | 1 |
| Mendez, GF | 1 |
| Hamlin, C | 1 |
| Lukjanowicz, M | 1 |
| Trzcińska-Butkiewicz, B | 1 |
| Brzosko, M | 1 |
| Xie, ML | 1 |
| Zhu, LJ | 1 |
| Gu, ZL | 1 |
| Moon, YS | 1 |
| Chun, P | 1 |
| Chung, S | 1 |
| Stopka, P | 1 |
| Zahin, M | 1 |
| Vareka, T | 1 |
| Janíková, L | 1 |
| Xie, W | 1 |
| Su, H | 1 |
| Xing, D | 1 |
| Cai, G | 1 |
| Du, L | 1 |
| Phuntuwate, W | 1 |
| Suthisisang, C | 1 |
| Chaloeiphap, P | 1 |
| Mackness, B | 1 |
| Mackness, M | 1 |
| Lai, CQ | 1 |
| Corella, D | 1 |
| Tsai, MY | 1 |
| Peacock, JM | 1 |
| Adiconis, X | 1 |
| Hixson, JE | 1 |
| Province, MA | 1 |
| Chatley, P | 1 |
| Badyal, DK | 1 |
| Calton, R | 1 |
| Khosla, PP | 1 |
| Wu, TJ | 1 |
| Ou, HY | 1 |
| Chou, CW | 1 |
| Hsiao, SH | 1 |
| Lin, CY | 1 |
| Kao, PC | 1 |
| Hegele, RA | 1 |
| Pollex, RL | 1 |
| Tokuno, A | 1 |
| Hirano, T | 1 |
| Hayashi, T | 1 |
| Mori, Y | 1 |
| Yamamoto, T | 1 |
| Nagashima, M | 1 |
| Shiraishi, Y | 1 |
| Ito, Y | 1 |
| Adachi, M | 1 |
| Bonds, DE | 1 |
| Lovato, LC | 1 |
| Crouse, JR | 1 |
| Elam, MB | 1 |
| Linz, PE | 1 |
| O'connor, PJ | 1 |
| Leiter, LA | 1 |
| Weiss, D | 1 |
| Lipkin, E | 1 |
| Fleg, JL | 1 |
| Arca, M | 1 |
| Montali, A | 1 |
| Pigna, G | 1 |
| Antonini, R | 1 |
| Antonini, TM | 1 |
| Luigi, P | 1 |
| Fraioli, A | 1 |
| Mastrantoni, M | 1 |
| Maddaloni, M | 1 |
| Letizia, C | 1 |
| Tanabe, J | 1 |
| Tamasawa, N | 1 |
| Yamashita, M | 1 |
| Matsuki, K | 1 |
| Murakami, H | 1 |
| Matsui, J | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Suda, T | 1 |
| Wu, J | 1 |
| Lin, JC | 1 |
| He, ZC | 1 |
| Ou, BR | 1 |
| Guo, HS | 1 |
| Ogino, K | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Du, ZY | 1 |
| Clouet, P | 1 |
| Degrace, P | 1 |
| Zheng, WH | 1 |
| Frøyland, L | 1 |
| Tian, LX | 1 |
| Liu, YJ | 1 |
| Landry, P | 1 |
| Dimitri, E | 1 |
| Tessier, S | 1 |
| Légaré, N | 1 |
| Tribble, DL | 1 |
| Musliner, TA | 1 |
| Steinmetz, J | 1 |
| Morin, C | 1 |
| Panek, E | 1 |
| Siest, G | 1 |
| Drouin, P | 1 |
| Blümcke, S | 1 |
| Schwartzkopff, W | 1 |
| Lobeck, H | 1 |
| Edmondson, NA | 1 |
| Prentice, DE | 1 |
| Blane, GF | 2 |
| Daubresse, JC | 1 |
| Vaverková, H | 2 |
| Kubasta, M | 1 |
| Zmeskal, A | 1 |
| Vrublovský, P | 1 |
| Skrabalová, H | 1 |
| Vlcek, L | 1 |
| Testa, S | 1 |
| Nurra, P | 1 |
| Nurra, V | 1 |
| Harvengt, C | 1 |
| Desager, JP | 1 |
| Fregnan, GB | 1 |
| Frigerio, L | 1 |
| Porta, R | 1 |
| Rössner, S | 1 |
| Olsson, AG | 1 |
| Saitoh, K | 1 |
| Mori, T | 1 |
| Kasai, H | 1 |
| Nagayama, T | 1 |
| Ohbayashi, S | 1 |
| Gresser, U | 1 |
| Gathof, BS | 1 |
| Gross, M | 1 |
| Bernard, PH | 1 |
| Lamouliatte, H | 1 |
| Le Bail, B | 1 |
| Bioulac-Sage, P | 1 |
| Quinton, A | 1 |
| Balabaud, C | 1 |
| Boissonnat, P | 2 |
| Salen, P | 3 |
| Guidollet, J | 2 |
| Ferrera, R | 1 |
| Dureau, G | 2 |
| Ninet, J | 1 |
| Renaud, S | 2 |
| de Lorgeril, M | 3 |
| Barth, JD | 1 |
| Mancini, GB | 1 |
| Lozada, A | 1 |
| Dujovne, CA | 2 |
| Kornitzer, M | 1 |
| Dramaix, M | 1 |
| Vandenbroek, MD | 1 |
| Everaert, L | 1 |
| Gerlinger, C | 1 |
| Berger, O | 1 |
| Zifko, U | 1 |
| Jellinger, K | 1 |
| Machacek, E | 1 |
| Grisold, W | 1 |
| Perova, NV | 3 |
| Ozerova, IN | 2 |
| Kalinina, AM | 1 |
| Pavlova, LI | 2 |
| Olfer'ev, AM | 3 |
| Mel'kina, OE | 1 |
| Golubev, MA | 1 |
| Oganov, RG | 2 |
| Novotný, D | 1 |
| Ficker, L | 1 |
| McPherson, R | 1 |
| Agnani, G | 1 |
| Lau, P | 1 |
| Edgar, AD | 1 |
| Marcel, YL | 1 |
| Schiel, R | 1 |
| Bambauer, R | 1 |
| Müller, UA | 1 |
| Perreault, S | 1 |
| Hamilton, VH | 1 |
| Lavoie, F | 1 |
| Grover, S | 1 |
| Farmer, JA | 1 |
| Gotto, AM | 1 |
| Jen, SL | 1 |
| Chen, JW | 1 |
| Lee, WL | 1 |
| Wang, SP | 1 |
| Durrington, P | 1 |
| Ooi, TC | 1 |
| Heinonen, T | 1 |
| Alaupovic, P | 1 |
| Davignon, J | 1 |
| Leiter, L | 1 |
| Lupien, PJ | 1 |
| Sniderman, AD | 1 |
| Tan, MH | 1 |
| Tremblay, G | 2 |
| Sorisky, A | 1 |
| Shurzinske, L | 1 |
| Black, DM | 1 |
| Adkins, JC | 1 |
| Faulds, D | 1 |
| Haak, T | 1 |
| Haak, E | 1 |
| Kusterer, K | 1 |
| Weber, A | 1 |
| Kohleisen, M | 1 |
| Usadel, KH | 1 |
| Packard, CJ | 3 |
| Ivanova, TN | 1 |
| Poliakova, ED | 1 |
| Koenig, W | 1 |
| Merval, R | 1 |
| Lebret, M | 1 |
| Delerive, P | 1 |
| Fadel, A | 1 |
| Chinetti, G | 1 |
| Maclouf, J | 1 |
| Tedgui, A | 1 |
| Hall, RR | 1 |
| Gholami, K | 1 |
| Tavakoli, N | 1 |
| Maleki, M | 1 |
| Shafiee, A | 1 |
| Jong, MC | 1 |
| Dahlmans, VE | 1 |
| Princen, HM | 1 |
| Havekes, LM | 1 |
| Paillard, F | 1 |
| Lacan, P | 1 |
| Richard, G | 1 |
| Bontemps, L | 1 |
| Belichard, P | 1 |
| Geyssant, A | 1 |
| Itti, R | 1 |
| Bairaktari, ET | 2 |
| Tzallas, CS | 1 |
| Tsimihodimos, VK | 1 |
| Liberopoulos, EN | 1 |
| Miltiadous, GA | 1 |
| Haffner, SM | 2 |
| Liamis, G | 1 |
| Rachiller, P | 1 |
| Ignacio Tortosa, J | 1 |
| Gylys, KH | 1 |
| Yong, QW | 1 |
| Thavintharan, S | 1 |
| Cheng, A | 1 |
| Chew, LS | 1 |
| Levin, A | 1 |
| Duncan, L | 1 |
| Djurdjev, O | 1 |
| Shapiro, RJ | 1 |
| Frohlich, J | 1 |
| Belanger, A | 1 |
| Dumas, R | 1 |
| Ross, S | 1 |
| Liang, B | 1 |
| McMaster, JC | 1 |
| Kroeger, EA | 1 |
| Hatch, GM | 1 |
| Mymin, D | 1 |
| Dembinski, T | 1 |
| Arthur, G | 1 |
| Shen, G | 1 |
| Man, RY | 1 |
| Choy, PC | 1 |
| Soska, V | 1 |
| Widimský, J | 1 |
| Hulínský, V | 1 |
| Balazovjech, I | 1 |
| Lánská, V | 1 |
| Ashraf, T | 1 |
| Betteridge, DJ | 1 |
| Colhoun, H | 1 |
| Armitage, J | 1 |
| Frost, RJ | 1 |
| Otto, C | 1 |
| Geiss, HC | 1 |
| Schwandt, P | 1 |
| Parhofer, KG | 1 |
| Lipscombe, J | 2 |
| Lewis, GF | 1 |
| Cattran, D | 1 |
| Bargman, JM | 2 |
| Kiortisis, DN | 1 |
| Millionis, H | 1 |
| Milosavljevic, D | 1 |
| Griglio, S | 1 |
| Le Naour, G | 1 |
| Rabasa-Lhoret, R | 1 |
| Rasamisoa, M | 1 |
| Avignon, A | 1 |
| Monnier, L | 1 |
| Zaborska, B | 1 |
| Kłoś, J | 1 |
| Sikora-Frac, M | 1 |
| Cybulska, B | 1 |
| Ceremuzyński, L | 1 |
| Yamashita, T | 1 |
| Nakamura, H | 1 |
| Blann, AD | 1 |
| Belgore, FM | 1 |
| Constans, J | 1 |
| Conri, C | 1 |
| Lip, GY | 2 |
| Forster, T | 1 |
| Kunstmann, S | 1 |
| Banditt, P | 1 |
| Lössner, A | 1 |
| Paramonova, IV | 1 |
| Akhmedzhanov, NM | 1 |
| Ritter, JL | 1 |
| Nabulsi, S | 1 |
| Wang, PR | 1 |
| Guo, Q | 1 |
| Ippolito, M | 1 |
| Wu, M | 1 |
| Milot, D | 1 |
| Ventre, J | 1 |
| Doebber, T | 1 |
| Chao, YS | 1 |
| Winegar, DA | 1 |
| Wilkison, WO | 1 |
| Lewis, MC | 1 |
| Ott, RJ | 1 |
| Tong, WQ | 1 |
| Brown, HR | 1 |
| Lehmann, JM | 1 |
| Kliewer, SA | 1 |
| Plunket, KD | 1 |
| Way, JM | 1 |
| Bodkin, NL | 1 |
| Hansen, BC | 1 |
| Puckey, LH | 1 |
| Knight, BL | 1 |
| Simek, J | 1 |
| Bostom, AG | 1 |
| Morishita, R | 1 |
| McDonald, KB | 1 |
| Garber, BG | 1 |
| Perreault, MM | 1 |
| Kiortsis, DN | 1 |
| Nagai, Y | 1 |
| Nishio, Y | 1 |
| Maegawa, H | 1 |
| Kikkawa, R | 1 |
| Kashiwagi, A | 1 |
| Calabresi, L | 1 |
| Gomaraschi, M | 1 |
| Villa, B | 1 |
| Omoboni, L | 1 |
| Dmitrieff, C | 1 |
| Franceschini, G | 1 |
| Idzior-Waluś, B | 1 |
| Caramelli, B | 1 |
| de Bernoche, CY | 1 |
| Sartori, AM | 1 |
| Sposito, AC | 1 |
| Santos, RD | 1 |
| Monachini, MC | 1 |
| Strabelli, T | 1 |
| Uip, D | 1 |
| Lee, KW | 1 |
| Felmeden, DC | 1 |
| Laperrière, L | 1 |
| Bourgeois, J | 1 |
| Achimastos, A | 1 |
| Liberopoulos, E | 1 |
| Nikas, S | 1 |
| Miltiadous, G | 1 |
| Delaval, D | 1 |
| Athyrou, VV | 1 |
| Demitriadis, DS | 1 |
| Kontopoulos, AG | 1 |
| Ruhn, G | 1 |
| deLorgeril, M | 1 |
| Bizollon, CA | 1 |
| Faucon, G | 1 |
| Guichard, JP | 1 |
| Levy-Prades-Sauron, R | 1 |
| Serrano, G | 1 |
| Fortea, JM | 1 |
| Latasa, JM | 1 |
| Millan, F | 1 |
| Janes, C | 1 |
| Bosca, F | 1 |
| Miranda, MA | 1 |
| Sásdi, A | 1 |
| Shepherd, J | 2 |
| Simpson, H | 1 |
| Williamson, CM | 1 |
| Pringle, S | 1 |
| MacLean, J | 1 |
| Lorimer, AR | 1 |
| Balfour, JA | 1 |
| McTavish, D | 1 |
| Heel, RC | 1 |
| Arsenio, L | 1 |
| Rossi, A | 1 |
| Brown, WV | 3 |
| Roberts, WC | 1 |
| Franzone, JS | 1 |
| Cirillo, R | 1 |
| Reboani, MC | 1 |
| Torrielli, MV | 1 |
| Pernigotti, LM | 1 |
| Knopp, RH | 2 |
| Walden, CE | 1 |
| Warnick, GR | 1 |
| Albers, JJ | 1 |
| Ginsberg, J | 1 |
| McGinnis, BM | 1 |
| Olivier, P | 1 |
| Plancke, MO | 1 |
| Marzin, D | 1 |
| Clavey, V | 1 |
| Sauzieres, J | 1 |
| Petit, D | 1 |
| Bonnefis, MT | 1 |
| Rey, C | 1 |
| Infante, R | 1 |
| Farquhar, JW | 1 |
| Feldman, EB | 1 |
| Goldberg, AC | 1 |
| Lasser, NL | 1 |
| Mellies, MJ | 1 |
| Palmer, RH | 1 |
| Torossian, F | 1 |
| Laredo, C | 1 |
| Leiss, O | 1 |
| Meyer-Krahmer, K | 1 |
| von Bergmann, K | 1 |
| Sirtori, CR | 1 |
| Montanari, G | 1 |
| Gianfranceschi, G | 1 |
| Sirtori, M | 1 |
| Galli, G | 1 |
| Bosisio, E | 1 |
| Mas, JL | 1 |
| Bousser, MG | 1 |
| Lacombe, C | 1 |
| Agar, N | 1 |
| Caslake, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia[NCT00093899] | Phase 3 | 611 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.[NCT01974297] | 194 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting | |||
| [NCT01414803] | Phase 4 | 180 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058] | Phase 4 | 41 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia[NCT00092573] | Phase 3 | 576 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia[NCT00092560] | Phase 3 | 587 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)[NCT00416741] | 2,000 participants (Actual) | Observational | 2005-02-28 | Completed | |||
| A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities[NCT00006412] | Phase 3 | 630 participants | Interventional | Completed | |||
| Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)[NCT00721305] | Phase 2 | 112 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376] | 221 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).[NCT04882293] | Phase 3 | 78 participants (Anticipated) | Interventional | 2022-02-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 37.1 |
| Group 2 - Diet/Exercise Only | 38.7 |
| Group 3 - Diet/Exercise + Fenofibrate | 40.7 |
| Group 4 - Diet/Exercise + Niacin | 41.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 44.8 |
non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 162.2 |
| Group 2 - Diet/Exercise Only | 165.4 |
| Group 3 - Diet/Exercise + Fenofibrate | 145.8 |
| Group 4 - Diet/Exercise + Niacin | 154 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 137.1 |
Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 195.6 |
| Group 2 - Diet/Exercise Only | 200.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 184 |
| Group 4 - Diet/Exercise + Niacin | 190.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 178.4 |
Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | ratio (Mean) |
|---|---|
| Group 1 - Usual Care | 5.2 |
| Group 2 - Diet/Exercise Only | 5.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 4.5 |
| Group 4 - Diet/Exercise + Niacin | 4.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 4 |
Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 199 |
| Group 2 - Diet/Exercise Only | 216.9 |
| Group 3 - Diet/Exercise + Fenofibrate | 155.1 |
| Group 4 - Diet/Exercise + Niacin | 177.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 135.6 |
"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Body cell mass | Fat mass | |
| Group 1 - Usual Care | 59.6 | 36.8 |
| Group 2 - Diet/Exercise | 67.3 | 37.5 |
| Group 3 - Diet/Exercise + Fenofibrate | 66.6 | 35.8 |
| Group 4 - Diet/Exercise + Niacin | 67.1 | 37.7 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 68.2 | 36.2 |
Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | micrograms/ml (Mean) | |||
|---|---|---|---|---|
| Fasting insulin | HOMA-IR | Insulin sensitvity index | Adiponectin | |
| Group 1 - Usual Care | 8.7 | 1.92 | 3.54 | 7.12 |
| Group 2 - Diet/Exercise Only | 6.7 | 1.38 | 4.95 | 6.04 |
| Group 3 - Diet/Exercise + Fenofibrate | 9.5 | 2.02 | 3.81 | 5.24 |
| Group 4 - Diet/Exercise + Niacin | 11.9 | 2.76 | 2.88 | 11.01 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 10.3 | 2.38 | 2.38 | 10.34 |
48 reviews available for fenofibrate and Hyperlipemia
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Anti-inflammatory role of fenofibrate in treating diseases.
Topics: Anti-Inflammatory Agents; Fenofibrate; Humans; Hyperlipidemias; Inflammation; Lipids; PPAR alpha | 2023 |
Protective role of peroxisome proliferator-activated receptor α agonists in skin barrier and inflammation.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Dermatitis; Fenofibrate; Filaggrin Prote | 2018 |
Lipids and Diabetic Retinopathy.
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipi | 2016 |
Treatment of hyperlipidaemia with fenofibrate and related fibrates.
Topics: Angiography; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fl | 2008 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coron | 2008 |
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2008 |
Myopathy with statin-fibrate combination therapy: clinical considerations.
Topics: Clofibric Acid; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias | 2009 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Fe | 2009 |
Combination of fenofibrate with non-statin drug regimens.
Topics: Animals; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2010 |
Fenofibric acid for hyperlipidemia.
Topics: Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2012 |
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Fenofibrate; Humans; | 2012 |
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Databases, Bibliographic; Diabetes Mellitus, Type 2; Drug Delivery Systems; | 2002 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary | 2002 |
Update on fenofibrate.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Fenofibrate; Humans; | 2002 |
Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
Topics: Adult; Anticholesteremic Agents; Biological Availability; Chemistry, Pharmaceutical; Clinical Trials | 2002 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2003 |
Musculoskeletal features of disorders of lipid metabolism and multicentric reticulohistiocytosis.
Topics: Fenofibrate; Histiocytosis, Non-Langerhans-Cell; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipi | 2004 |
Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
Topics: Biological Availability; Cholesterol, HDL; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipi | 2002 |
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niac | 2004 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Human | 2004 |
[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2004 |
[Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature].
Topics: Contraindications; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; | 2006 |
Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
Topics: Azetidines; Drug Combinations; Drug Synergism; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypo | 2007 |
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyp | 2007 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
An update on lipid-lowering therapy.
Topics: Aged; Anticholesteremic Agents; Colestipol; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA R | 1995 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru | 1994 |
[Necrotizing myopathy with antilipemic agents. Case report and review of the literature].
Topics: Aged; Biopsy; Creatine Kinase; Electromyography; Fenofibrate; Humans; Hyperlipidemias; Long-Term Car | 1993 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agent | 1997 |
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinica | 1997 |
Overview of fenofibrate.
Topics: Apolipoprotein C-III; Apolipoproteins C; Arteriosclerosis; Coronary Disease; Fenofibrate; Humans; Hy | 1998 |
Diabetes, hyperlipidemia, and coronary artery disease.
Topics: Apolipoproteins B; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fenofibrat | 1999 |
Micronized fenofibrate: a new fibric acid hypolipidemic agent.
Topics: Clinical Trials as Topic; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 1999 |
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Red | 2000 |
[Fenofibrate].
Topics: Animals; Arteriosclerosis; Coronary Disease; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Age | 2001 |
[Pleiotrophic effect of anti-hyperlipemic agents].
Topics: Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic | 2001 |
Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as To | 2001 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen.
Topics: Aged; Bezafibrate; Cross Reactions; Dermatitis, Photoallergic; Drug Eruptions; Female; Fenofibrate; | 1992 |
Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Topics: Clinical Trials as Topic; Fenofibrate; Humans; Hyperlipidemias; Lipids; Lipoproteins | 1990 |
Review of European clinical experience with fenofibrate.
Topics: Clinical Trials as Topic; Europe; Fenofibrate; Gastrointestinal Diseases; Humans; Hyperlipidemias; P | 1989 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibra | 1989 |
Safety of fenofibrate--US and worldwide experience.
Topics: Clinical Trials as Topic; Europe; Fenofibrate; Humans; Hyperlipidemias; Propionates; United States | 1989 |
Focus on fenofibrate.
Topics: Anticholesteremic Agents; Cholesterol; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 1988 |
104 trials available for fenofibrate and Hyperlipemia
| Article | Year |
|---|---|
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Topics: Adult; Double-Blind Method; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemi | 2022 |
Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Copper; Cro | 2013 |
Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia.
Topics: Adult; Aged; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Synergism; Female; Fen | 2015 |
Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, LDL; Drug Therapy, Comb | 2017 |
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipo | 2008 |
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Topics: Age Distribution; Aged; Amputation, Surgical; Body Height; Cardiovascular Diseases; Diabetes Mellitu | 2009 |
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Electrocardiography; Female; Fenofibrate; Fo | 2010 |
[Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperuricemia; Hypolipidemic Agents; Lipi | 2009 |
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Topics: Adult; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Fe | 2011 |
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
Topics: Aged; Apolipoproteins; Belgium; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind M | 2010 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double | 2011 |
Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Ty | 2012 |
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemica | 2012 |
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial.
Topics: Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Postpra | 2013 |
Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Chromatography, High Pressure Liquid; Creat | 2002 |
Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.
Topics: Antioxidants; Blood Glucose; Blood Pressure; Coenzymes; Diabetes Mellitus, Type 2; Dietary Supplemen | 2002 |
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.
Topics: Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Feno | 2002 |
Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.
Topics: Adult; Aged; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; Female; Fenofibrate; Humans; | 2002 |
Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.
Topics: Adult; Apolipoproteins B; Biguanides; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Dietary Fats; Do | 2003 |
Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Male; Middle Aged; Pravastat | 2003 |
Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.
Topics: Aged; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fenofibrate; Humans; Hydroxymeth | 2002 |
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Apolipoproteins B; Apolipoproteins E; Aryldia | 2003 |
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Metho | 2003 |
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrat | 2003 |
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Topics: Cholesterol; Creatinine; Cysteine; Female; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperhomoc | 2003 |
[Effect of fluvastatin and fenofibrate on reactive oxygen species generation and lipid peroxidation in patients with dyslipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastati | 2003 |
[Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Catalase; Fatty Acids, Monounsaturated; Female; | 2003 |
[Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fem | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocystein | 2003 |
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Topics: Adipose Tissue; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Fatty Acids, Nonesterified; Fenofi | 2003 |
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorva | 2004 |
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Atorvastatin; Choles | 2003 |
[Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Topics: Adult; Aged; Coronary Disease; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethyl | 2003 |
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Topics: Adult; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, | 2004 |
Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.
Topics: Adult; Arginine; Biomarkers; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Meth | 2004 |
Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Insul | 2004 |
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Topics: Adult; Aged; Atorvastatin; Drug Therapy, Combination; Fenofibrate; Heptanoic Acids; Humans; Hydroxym | 2004 |
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Topics: Acetylglucosaminidase; Adult; Aged; alpha-Tocopherol; Ascorbic Acid; Cholesterol; Czech Republic; Di | 2004 |
Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia.
Topics: Brachial Artery; Coronary Artery Disease; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemi | 2004 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Prote | 2004 |
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients.
Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Cholesterol; Female; Fenofibrate; Humans; Hyper | 2004 |
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Coronary Disease; Delayed-Action Preparat | 2004 |
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Topics: Adolescent; Adult; Aged; Animals; Apolipoprotein A-I; Cholesterol, HDL; Female; Fenofibrate; Gemfibr | 2005 |
Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Japan; Male; Middle | 2004 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Chemokine CCL2; Double-Blind Method; Drug Administration | 2005 |
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fema | 2005 |
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fema | 2005 |
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fema | 2005 |
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fema | 2005 |
Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
Topics: Adult; Aged; Cholesterol; Drug Administration Schedule; Female; Fenofibrate; Humans; Hyperlipidemias | 2004 |
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; | 2005 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, C | 2005 |
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo | 2005 |
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo | 2005 |
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo | 2005 |
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypo | 2005 |
[Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibra | 2005 |
Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus.
Topics: Coenzymes; Diabetes Mellitus, Type 2; Disease Progression; Female; Fenofibrate; Humans; Hyperlipidem | 2006 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlip | 2006 |
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over | 2006 |
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
Topics: Adult; Antiretroviral Therapy, Highly Active; Combined Modality Therapy; Diet, Fat-Restricted; Exerc | 2006 |
Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biomarkers; Carotid Artery Diseases; Demography; | 2006 |
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Topics: Azetidines; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastati | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; F | 2006 |
Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.
Topics: Adult; Aryldialkylphosphatase; Cholesterol, HDL; Fenofibrate; Gene Frequency; Genotype; Humans; Hype | 2008 |
Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein A-V; Apolipoprotein | 2007 |
Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Creatine | 2007 |
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Topics: Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cholesterol; Diabetes Mellitus | 2007 |
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Sched | 2007 |
Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Endothelin-1; Endothelium, Vascular; Female; Fenofibrate; Hep | 2007 |
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-B | 2008 |
A comparison of fenofibrate and clofibrate hypolipidemic effects.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Fenofibrate; Humans; Hy | 1980 |
[Experience with the hypolipidemic drug Lipanthyl].
Topics: Clinical Trials as Topic; Female; Fenofibrate; Humans; Hyperlipidemias; Male; Middle Aged; Propionat | 1982 |
Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study.
Topics: Adolescent; Adult; Aged; Belgium; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Compounding; | 1994 |
[The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels].
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoprotein | 1996 |
[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias].
Topics: Dosage Forms; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, | 1995 |
The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.
Topics: Adult; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; | 1996 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Topics: Adult; Aged; Cross-Over Studies; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipi | 1997 |
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Diet; Female; Fenofibrate; H | 1997 |
[Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
Topics: Adult; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hyperc | 1998 |
Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoprote | 1998 |
Lipid-lowering drugs and homocysteine.
Topics: Amino Acids; Coronary Disease; Double-Blind Method; Fenofibrate; Homocysteine; Humans; Hyperlipidemi | 1999 |
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
Topics: Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyspepsia; Exercise Test; F | 1999 |
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenof | 1999 |
A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipid | 2000 |
[Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
Topics: Adult; Aged; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Feno | 1999 |
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies | 2001 |
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Drug Combinations; Female; Fenofibrate; Fibrinog | 2000 |
Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Topics: Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fe | 2001 |
[Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipide | 2000 |
Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
Topics: Cross-Over Studies; Double-Blind Method; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperlipidem | 2001 |
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
Topics: Arteriosclerosis; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Folic | 2001 |
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Topics: Adult; Arm; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Fenofibrate; H | 2001 |
Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
Topics: Adult; Brachial Artery; Double-Blind Method; Fenofibrate; Hemodynamics; Humans; Hydroxymethylglutary | 2002 |
Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.
Topics: Analysis of Variance; Arteriosclerosis; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; E | 2002 |
Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate.
Topics: Adult; Aged; CD4 Lymphocyte Count; Cholesterol; Female; Fenofibrate; HIV Infections; HIV Protease In | 2001 |
A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Topics: Adult; Drug Administration Schedule; Fasting; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA | 2002 |
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
Topics: Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hype | 2002 |
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Ch | 2002 |
Review of European clinical experience with fenofibrate.
Topics: Clinical Trials as Topic; Europe; Fenofibrate; Gastrointestinal Diseases; Humans; Hyperlipidemias; P | 1989 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibra | 1989 |
Safety of fenofibrate--US and worldwide experience.
Topics: Clinical Trials as Topic; Europe; Fenofibrate; Humans; Hyperlipidemias; Propionates; United States | 1989 |
Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipopro | 1987 |
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipide | 1987 |
Cochleovestibular disorders and hyperlipidemia. A controlled trial with fenofibrate.
Topics: Adult; Aged; Clinical Trials as Topic; Cochlea; Double-Blind Method; Female; Fenofibrate; Hearing; H | 1986 |
Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
Topics: Adult; Biological Availability; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipid | 1985 |
160 other studies available for fenofibrate and Hyperlipemia
| Article | Year |
|---|---|
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
Topics: Alcohols; Animals; Cells, Cultured; Cholesterol, HDL; Diabetes Mellitus; Dicarboxylic Acids; Dose-Re | 2004 |
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
Topics: Animals; Benzofurans; Carboxylic Acids; Cholesterol; Cricetinae; Dogs; Humans; Hyperlipidemias; Hypo | 2005 |
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Topics: Acetates; Animals; Apolipoprotein A-I; Cell Line; Cricetinae; Female; Humans; Hyperlipidemias; Hypog | 2007 |
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
Topics: Animals; Dietary Fats; Fibric Acids; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Hypolipide | 2011 |
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
Topics: Animals; Anti-Obesity Agents; Bile Acids and Salts; Butyrates; Dietary Fats; Fatty Liver; Feces; Fee | 2012 |
2,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for antihyperlipidemic agents.
Topics: Animals; Drug Design; Hepatocytes; Hyperlipidemias; Hypolipidemic Agents; Imidazoles; Male; Models, | 2013 |
Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
Topics: Animals; Antioxidants; Disease Models, Animal; Diterpenes; Humans; Hyperlipidemias; Hypolipidemic Ag | 2013 |
Synthesis and in-vivo hypolipidemic activity of some novel substituted phenyl isoxazol phenoxy acetic acid derivatives.
Topics: Acetates; Androstenols; Animals; Female; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Rats; | 2014 |
Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents.
Topics: Animals; Antioxidants; Chalcone; Disease Models, Animal; Drug Design; Hyperlipidemias; Hypolipidemic | 2014 |
5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.
Topics: Animals; Diet, High-Fat; Fibric Acids; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Live | 2018 |
1,3-Benzodioxole-based fibrate derivatives as potential hypolipidemic and hepatoprotective agents.
Topics: Animals; Diet, High-Fat; Dioxoles; Dose-Response Relationship, Drug; Hyperlipidemias; Hypolipidemic | 2021 |
Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.
Topics: Atorvastatin; Bezafibrate; Deafness; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperli | 2022 |
Spectral-Domain OCT Imaging of Lipemia Retinalis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Diabetes Complications; Drug Therapy, Combinati | 2021 |
Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management.
Topics: Diet, Fat-Restricted; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Pregnancy | 2022 |
A nano-enabled biotinylated anti-LDL theranostic system to modulate systemic LDL cholesterol.
Topics: Animals; Cholesterol, LDL; Fenofibrate; Hyperlipidemias; Lipoproteins, LDL; Precision Medicine; Qual | 2022 |
Successful multimodal treatment of extreme hypertriglyceridemia in a juvenile diabetic dog.
Topics: Animals; Combined Modality Therapy; Diabetes Mellitus; Diabetic Ketoacidosis; Dog Diseases; Dogs; Fe | 2023 |
Fenofibrate alleviates insulin resistance by reducing tissue inflammation in obese ovariectomized mice.
Topics: Animals; Female; Fenofibrate; Humans; Hyperlipidemias; Inflammation; Insulin Resistance; Liver; Mice | 2023 |
Targeted changes in blood lipids improves fibrosis in renal allografts.
Topics: Allografts; Animals; Cholesterol; Fatty Acids, Omega-3; Fenofibrate; Fibrosis; Humans; Hyperlipidemi | 2023 |
[Effects of сramizol on expression of the ApoA1 gene in rats with experimental hyperlipidemia].
Topics: Animals; Apolipoprotein A-I; Cholesterol; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Imidaz | 2019 |
Pharmacological screening of fenofibrate-loaded solid dispersion in fructose-induced diabetic rat.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Drug Compounding; Fenofibrate; Hepatobiliary | 2020 |
[Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model].
Topics: Animals; Cholesterol, HDL; Dyslipidemias; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Rats; | 2020 |
Lipid status and linear relationship between total cholesterol and triglycerides in glycogen storage disease type I.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Female; Fenofibrate; Gemfibrozil; Glucose-6 | 2020 |
Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs.
Topics: Animals; Dog Diseases; Dogs; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Nanoparticles; Pros | 2021 |
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stabi | 2021 |
The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
Topics: Adipocytes, Brown; Adipose Tissue; Animals; Energy Metabolism; Fenofibrate; Fibroblast Growth Factor | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Model design for screening effective Antihyperlipidemic drugs using zebrafish system.
Topics: Animals; Atorvastatin; Biomarkers; Cholesterol; Diet, High-Fat; Disease Models, Animal; Drug Discove | 2017 |
Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cholesterol, HDL; Delayed-A | 2018 |
Coreopsis Tinctoria Modulates Lipid Metabolism by Decreasing Low-Density Lipoprotein and Improving Gut Microbiota.
Topics: Adult; Animals; Bacteria; Coreopsis; Disease Models, Animal; DNA, Bacterial; Female; Fenofibrate; Ga | 2018 |
Pharmacological evaluation of Convolvulus pluricaulis as hypolipidaemic agent in Triton WR-1339-induced hyperlipidaemia in rats.
Topics: Animals; Atherosclerosis; Biomarkers; Convolvulus; Disease Models, Animal; Female; Fenofibrate; Hype | 2018 |
A UPLC/MS/MS method for comprehensive profiling and quantification of fatty acid esters of hydroxy fatty acids in white adipose tissue.
Topics: Adipose Tissue, White; Animals; Chromatography, Liquid; Cricetinae; Fatty Acids; Fenofibrate; Hyperl | 2018 |
Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Brain; Butyrylcholinesterase; Fenofibrate; Hyperlipidemias; Hypol | 2019 |
Improvement of the dissolution rate and bioavailability of fenofibrate by the supercritical anti-solvent process.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line, Tumor; Cell Survival; Cholesterol | 2019 |
Assessment of hypolipidemic, anti-inflammatory and antioxidant properties of medicinal plant Erica multiflora in triton WR-1339-induced hyperlipidemia and liver function repair in rats: A comparison with fenofibrate.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ericaceae; Fenofibrate; Hyperlipidemias; Hypolipide | 2019 |
Formulation and optimization of fenofibrate lipospheres using Taguchi's experimental design.
Topics: Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Fatty Alcohols; Feno | 2013 |
Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholest | 2013 |
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expressio | 2014 |
The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.
Topics: Animals; Cell Proliferation; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Insulin; Insulin-Li | 2014 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, | 2014 |
Lipemia retinalis following systemic steroids for neurocysticercosis in a juvenile diabetic.
Topics: Adolescent; Anti-Inflammatory Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; | 2015 |
Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.
Topics: 3-Hydroxybutyric Acid; Animals; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatin | 2014 |
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenof | 2015 |
[Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Diet, High-Fat; Drugs, Chinese Herbal; Fenofibrat | 2017 |
Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Diabetes Mellitus, Experimental | 2009 |
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydrotherapy; Hyperlipidemias; Hypolipidemic | 2008 |
Milky plasma, diabetes, and severe hyponatremia.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hyponat | 2009 |
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofi | 2010 |
The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
Topics: Aged; Aged, 80 and over; Aging; Bilirubin; Clinical Laboratory Techniques; Creatine Kinase; Diabetes | 2011 |
Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.
Topics: Adult; Apolipoproteins E; Dietary Fats; Fasting; Female; Fenofibrate; Genotype; Humans; Hyperlipidem | 2010 |
Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Cricetinae; Dietary Fats; Fenofibrate; Hyperlipidemias | 2010 |
Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
Topics: Carotid Artery Diseases; Cholesterol, HDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidem | 2010 |
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Ex | 2011 |
Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cricetinae; Fatty Acids; Female; Fe | 2011 |
Not a graves' situation.
Topics: Atorvastatin; Biomarkers; Diagnosis, Differential; Drug Therapy, Combination; Eye Diseases; Fenofibr | 2011 |
Hypolipidemic activity of Symplocos cochinchinensis S. Moore leaves in hyperlipidemic rats.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Diet | 2012 |
Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents.
Topics: Animals; Carboxylic Acids; Cholesterol; Diabetes Mellitus, Experimental; Fenofibrate; Flavonoids; Hy | 2012 |
Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Databases, Factual; Double-Blind Method; Drug Comb | 2012 |
Influence of lipid imbalance on butyrylcholinesterase activity and biotransformation efficiency.
Topics: Adipose Tissue, White; Animals; Benzoylcholine; Biotransformation; Body Weight; Butyrylcholinesteras | 2012 |
False estimates of elevated creatinine.
Topics: Creatinine; Diagnosis, Differential; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hyperl | 2012 |
Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C.
Topics: Adult; Aged; Creatine Kinase; Creatinine; Cystatin C; Female; Fenofibrate; Glomerular Filtration Rat | 2012 |
Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
Topics: Adolescent; Adult; Aged; Biological Availability; Cholesterol, HDL; Clinical Trials as Topic; Female | 2002 |
A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic.
Topics: Cholesterol, HDL; Female; Fenofibrate; Hospitals, University; Humans; Hyperlipidemias; Hypolipidemic | 2002 |
Effects of various fibrates on serum alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; H | 2002 |
Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
Topics: Adult; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol; Diabetes | 2002 |
Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Gem | 2002 |
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Disease; Fenofibrate; Heptanoic Acids; Humans | 2003 |
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
Topics: Aged; Chi-Square Distribution; Coronary Disease; Cross-Over Studies; Female; Fenofibrate; Gemfibrozi | 2002 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female | 2003 |
Long-term remission from gout associated with fenofibrate therapy.
Topics: Fenofibrate; Gout; Humans; Hyperlipidemias; Hyperuricemia; Hypolipidemic Agents; Lipids; Male; Middl | 2003 |
[HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocy | 2003 |
Clinical pharmacokinetics of fenofibrate.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fenofibrate; Humans; Hyperlipidemias; Hypoli | 2003 |
Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model.
Topics: Animals; Bile Acids and Salts; Blood Glucose; Cricetinae; Diabetes Mellitus; Fats; Feces; Fenofibrat | 2003 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholestero | 2003 |
A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyp | 2003 |
Fenofibrate monotherapy induced rhabdomyolysis.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Middl | 2003 |
Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography.
Topics: Adult; Chromatography, High Pressure Liquid; Cushing Syndrome; Diagnosis, Differential; Female; Feno | 2003 |
A patient with hyperlipidemia who had a gallbladder stone caused by administration of fenofibrate.
Topics: Cholelithiasis; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Tom | 2003 |
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluv | 2003 |
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
Topics: Adult; Anticholesteremic Agents; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; HIV-1 | 2003 |
Fenofibrate-induced myopathy.
Topics: Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Muscular Diseases | 2004 |
In vivo model for dyslipidemia with diabetes mellitus in hamster.
Topics: Animals; Cricetinae; Diabetes Mellitus, Experimental; Dietary Fats; Disease Models, Animal; Fenofibr | 2003 |
Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Drug T | 2004 |
Risk of adverse events with fibrates.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidem | 2004 |
Decrease in serum dehydroepiandrosterone level after fenofibrate treatment in males with hyperlipidemia.
Topics: Adult; Aged; Dehydroepiandrosterone; Fenofibrate; Humans; Hyperlipidemias; Male; Middle Aged; Statis | 2005 |
Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
Topics: Atorvastatin; Cells, Cultured; Clofibric Acid; Cytokines; Fenofibrate; Fibrinolytic Agents; Heptanoi | 2005 |
Management of mixed hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyp | 2005 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cho | 2005 |
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients.
Topics: Adult; Anti-Inflammatory Agents; Body Mass Index; C-Reactive Protein; Fenofibrate; Humans; Hyperlipi | 2005 |
Simvastatin, fenofibrate, and rhabdomyolysis.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Hy | 2005 |
A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas.
Topics: Diabetes Mellitus, Type 2; Erythrocyte Aggregation; Female; Fenofibrate; Humans; Hyperlipidemias; Hy | 2005 |
Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia.
Topics: Aging; Animals; Fenofibrate; Hyperlipidemias; Lipids; Liver; Male; PPAR alpha; Rats; Rats, Sprague-D | 2005 |
Ezetimibe coadministered with fenofibrate: some safety questions.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Drug Combinations; Ezetimibe; Fenofibrate; Hu | 2005 |
Treatment of hyperlipidemia associated with Niemann-Pick disease type B by fenofibrate.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Child, Preschool; Fenofibrate; Humans; Hyperlipid | 2006 |
PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Fenofibrate; Humans; Hyperlipidemias; Hypertensio | 2006 |
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Di | 2006 |
[Ezetimibe with statins].
Topics: Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglu | 2006 |
The role of fibrates in a statin world.
Topics: Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperl | 2006 |
[Effect of polymorphism of human intestinal fatty acid binding protein gene on the therapeutic efficacy of fenofibrate].
Topics: Aged; Apolipoproteins; Fatty Acid-Binding Proteins; Female; Fenofibrate; Gene Frequency; Genotype; H | 2006 |
Hypolipidaemic activity of aqueous Ocimum basilicum extract in acute hyperlipidaemia induced by triton WR-1339 in rats and its antioxidant property.
Topics: Animals; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Hyperlipidemias; Hyp | 2006 |
Correction to the FIELD study report.
Topics: Coronary Disease; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Proportional Hazards M | 2006 |
Therapeutic effect of osthole on hyperlipidemic fatty liver in rats.
Topics: Animals; Antioxidants; Cnidium; Coumarins; Fatty Liver; Fenofibrate; Hyperlipidemias; Hypolipidemic | 2007 |
Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.
Topics: Ananas; Animals; Blood Glucose; Cholesterol; Dietary Fats; Dose-Response Relationship, Drug; Enzyme | 2007 |
Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates.
Topics: Apolipoprotein A-V; Apolipoproteins A; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; L | 2007 |
The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Chole | 2008 |
[Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats].
Topics: Animals; Atherosclerosis; Cell Adhesion; Endothelium, Vascular; Fenofibrate; Hyperlipidemias; Inflam | 2007 |
Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp ( Ctenopharyngodon idella) fed a high-fat diet.
Topics: Animal Nutritional Physiological Phenomena; Animals; Carps; Combined Modality Therapy; Dietary Fats; | 2008 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; | 2008 |
Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bilirubin; Child; Child, Preschool; Cholesterol; Fenofibrat | 1981 |
Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Microb | 1983 |
[Procetofen: hemolytic effect in subjects with G6PD deficiency. Description of a case].
Topics: Fenofibrate; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Hyperlipidemias; Male; Mi | 1982 |
[Pharmacokinetics of fenofibrate in man (author's transl)].
Topics: Colestipol; Drug Interactions; Fenofibrate; Half-Life; Humans; Hyperlipidemias; Hypolipidemic Agents | 1980 |
Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731).
Topics: Animals; Cholesterol; Clofibrate; Dioxoles; Dose-Response Relationship, Drug; Female; Fenofibrate; H | 1981 |
Effects of combined procetofene--nicotinic acid therapy in treatment of hypertriglyceridaemia.
Topics: Aged; Cholesterol; Clofibrate; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lipo | 1980 |
[Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits].
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Fenofibrate; Gene Deletion; Hyperlipidemias; Hypolipidem | 1995 |
Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome?
Topics: Benzbromarone; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Gout; Humans; Hyperlipi | 1994 |
[Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate].
Topics: Antibodies, Antinuclear; Blood Chemical Analysis; Chemical and Drug Induced Liver Injury; Chemical a | 1994 |
The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.
Topics: Adolescent; Adult; Aged; Drug Tolerance; Fenofibrate; Heart Transplantation; Humans; Hyperlipidemias | 1994 |
Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Carrier Proteins; Child; Child, Preschool; Cholester | 1996 |
Fenofibrate improves microcirculation in patients with hyperlipidemia.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Microcirculat | 1998 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox | 1998 |
Micronized fenofibrate in the management of dyslipidemia.
Topics: Drug Compounding; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 1998 |
Detecting and correcting hyperlipidemia.
Topics: Algorithms; Decision Trees; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; | 1998 |
Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice.
Topics: Animals; Apolipoproteins C; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Mice; Mice, | 1998 |
Effect of fenofibrate on serum uric acid levels.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Fenofibrate; Humans; Hyperlipidemias | 1999 |
[Reversibility of severe hyperlipemia secondary to indinavir with micronized phenofibrate].
Topics: Administration, Oral; Adult; Fenofibrate; Hemophilia A; HIV Infections; HIV Protease Inhibitors; Hum | 1999 |
The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Glucose Tolerance Test; Humans; Hyperlipidem | 1999 |
The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Cholesterol; Cholesterol, LDL; Chromatography, Gas; Endothe | 2000 |
[Micronized fenofibrate and LDL-cholesterol subfractions].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agent | 1999 |
Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Topics: Coronary Disease; Cost Savings; Cost-Benefit Analysis; Fenofibrate; Glucose Intolerance; Humans; Hyd | 2000 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease | 2000 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
Deterioration in renal function associated with fibrate therapy.
Topics: Adult; Aged; Creatinine; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Ki | 2001 |
Rare side-effects of fenofibrate.
Topics: Aged; Cholecystectomy; Drug Hypersensitivity; Female; Fenofibrate; Fever; Humans; Hyperlipidemias; H | 2001 |
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Endothelial Growth Factors; Fatty Acids, Mo | 2001 |
Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
Topics: Adult; Cholesterol; Female; Fenofibrate; HIV Protease Inhibitors; Humans; Hyperlipidemias; Hypolipid | 2001 |
Fibrate-induced increase in blood urea and creatinine.
Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyp | 2001 |
[Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
Topics: Adult; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression | 2001 |
Phospholipid composition of high-density lipoproteins reflects lipolysis of triglyceride-rich lipoproteins during hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Cardiolipins; Cholesterol; Cholesterol, HDL; Fenofibrate; Humans; H | 2001 |
Fenofibrate-Induced elevation in serum creatinine.
Topics: Adult; Aged; Combined Modality Therapy; Creatinine; Female; Fenofibrate; Humans; Hyperlipidemias; Hy | 2001 |
High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Cholesterol, VLDL; Cricetinae; Diabetes Mellitus, Experime | 2001 |
Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
Topics: Amino Acid Sequence; Animals; Apolipoproteins; Base Sequence; Blood Glucose; Blotting, Western; Body | 2001 |
Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects.
Topics: Aged; Amino Acid Substitution; Bezafibrate; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemia | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Creatinine; Fenofibrate; Gemfibrozil; Glomerular Filtration Rate; Homocysteine; Humans; Hyperlipidem | 2001 |
Pancreatitis associated with simvastatin plus fenofibrate.
Topics: Aged; Drug Therapy, Combination; Fatal Outcome; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic | 2002 |
Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
Topics: Adult; Aged; Biomarkers; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; M | 2001 |
Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.
Topics: Adipose Tissue; Animals; Blood Pressure; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; DNA-Bind | 2002 |
Statins and the assessment of endothelial function.
Topics: Endothelium, Vascular; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlip | 2002 |
The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Drug Therapy | 2002 |
Relation between arteriographically diagnosed femoral atherosclerosis and serum lipids. Prevalence and treatment in hyperlipidaemic subjects.
Topics: Adult; Aged; Aorta, Abdominal; Aortic Aneurysm; Arteriosclerosis; Drug Therapy, Combination; Femoral | 1992 |
Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Cyclosporine; Fenofibrate; Heart Transplantation; | 1992 |
Protective role of lipanthyl in women taking oral contraceptives.
Topics: Adult; Contraceptives, Oral; Female; Fenofibrate; Humans; Hyperlipidemias | 1991 |
[Antilipemic agents and postprandial lipidemia].
Topics: Cholesterol; Chylomicrons; Coronary Artery Disease; Dietary Fats; Diterpenes; Female; Fenofibrate; H | 1990 |
[Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives].
Topics: Adult; Bezafibrate; Drug Evaluation; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Lipi | 1989 |
Effect of teomorfolin [N-(7'-theophylline acetyl)morpholine], a new drug, on dislipidaemic conditions induced in the rat.
Topics: Adenosine Diphosphate; Animals; Blood Glucose; Diet, Atherogenic; Epoprostenol; Erythrocyte Deformab | 1988 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofib | 1988 |
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperl | 1988 |
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fem | 1986 |
Hyperlipidemic dementia.
Topics: Clofibrate; Dementia; Female; Fenofibrate; Humans; Hyperlipidemias; Middle Aged | 1985 |
Effects of fenofibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in hypertriglyceridaemic subjects.
Topics: Fenofibrate; Humans; Hyperlipidemias; Lipoproteins, LDL; Male; Propionates; Receptors, LDL; Triglyce | 1985 |